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ABSTRACT
 
The kappa opioid agonist U-50V488 is known to decrease
 
the locomotor activity of adult rats. In contrast, U­
50,488 dramatically increases the locomotor activity of
 
preweanling rats. Although the mechanisms responsible
 
for U-50,488's paradoxical effects are uncertain, it is
 
possible that U-50,488 was increasing locomotor activity
 
by activating a dopaminergic process. To assess this
 
kappa/DA interaction 17- and 80-day-old rats were
 
treated with the DA antagonist flupenthixol (0.025—0.8
 
mg/kg, i.p.) prior to an injection of U-50,488 (5.0
 
mg/kg, S.C.). Flupenthixol did block U-50,488-induced
 
activity, but it is possible that this was due to a
 
general depression in motoric functioning. Therefore,
 
the effects of U-50,488, NPA (a direct DA agonist), and
 
amphetamine (an,indirect DA agonist) were assessed in
 
17- and 80-day-old rats. Consistent with previous
 
studies, U-50,488 increased the locomotor activity of
 
preweanling rats, while having no effect on the activity
 
of adult rats. NPA attenuated U-50,488-induced
 
locomotor activity, in a dose-dependent manner,
 
while amphetamine had few effects on U-50,488's activity
 
enhancing effects. In these experiments Fos was
 
assessed in order to determine the specific brain
 
regions where U-50,488 was working. Fos
 
immunohistochemistry indicated that U-50,488 increased
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Fos expression in several brain regions of the
 
preweanling rat, including: olfactory tubercles,
 
habenula, striatum, and preoptic area. Importantly, NPA
 
reduced U-50,488-induced Fos induction in the striatum.
 
In an additional set of experiments, cross-sensitization
 
was assessed to further examine the kappa/DA interaction
 
in the preweanling rat. At 11 days of age, rats were
 
given an injection of amphetamine or NPA for 5
 
consecutive days. Following a two day interval (at 17
 
days of age), rats received a challenge injection of U­
50,488 or the same DA agonist again. There was no
 
cross-sensitization between U-50,488 and either of the
 
DA agonists, suggesting that U-50,488's locomotor
 
activating effects are not directly mediated through a
 
dopaminergic mechanism. Therefore, when taken together
 
these results suggest that U-50,488's ability to
 
paradoxically increase the locomotor activity of
 
preweanling rats is not due to actions on DA neurons.
 
Rather, the kappa opioid and DA systems appear to have
 
an antagonistic relationship, as kappa opioid and DA
 
agonists reciprocally inhibit one another.
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Introduction
 
Ontogenetic Research Strategy
 
The ontogenetic research strategy has become an
 
increasingly popular approach for studying the
 
neurobiological mechanisms underlying behayior. Besides
 
the obvious advantage of enhancing our knowledge of the
 
developing organismj the Qhtogendtic strategy provides
 
an additional tool for determining those mechanisms or
 
systems mediating behavior. More specifically, as the
 
animal matures new behaviors emerge as the underlying
 
neurobiological mechanisms become functional. Hence,
 
the ontogenetic process can itself be used as a tool to
 
pinpoint those receptor or neurotransmitter systems
 
mediating a particular behavior (see Spear, 1979; Zolman
 
& McDougall, 1983, for additional reviews).
 
Recently, a number of different laboratories have
 
used the ontogenetic research strategy to study the
 
mediation of behavior by the dopamine and kappa opioid
 
receptor systems. In each case, these receptor systems
 
have been found to exhibit both quantitative and
 
qualitative changes across development. Quantitative
 
changes are the most Common, as drug responsiveness
 
often shows a monotonic increase according to age. For
 
example, dopamine agonists (e.g., apomorphine and
 
quinpirole) increase the locomotor activity of rats as
 
young as 4 days of age (Camp & Rudy, 1987; McDougall,
 
Arnold, & Ncnneman, 1990; Moody & Spear, 1992; Shalaby& 
Spear, 1980). Apomorpliine and quinpirole induce 
identical behaviors in older rat pups and adults, but 
the potency of these dopamine-acting drugs increases 
linearly with age (Moody & Spear, 1992; Shalaby & Spear, 
.'i980-)v. . ■ ' 
of more interest, are those psychopharmacological 
effects which exhibit qualitative changes across 
development. For instance, the dopamine mediated
 
behaviors of preweanling rats are sometimes
 
characterized by the emergence of new behaviors (e.g,,
 
grooming), and the occurrence of age-specific behayiors
 
(e.g., wal1 climbing), which are only found during a
 
restricted period of developmeht (Mopdy & Spear, 1992;
 
Shalaby & Spear, 1980). The kappa opioid system also
 
shows qualitative ontogenetic differences, as high doses
 
of U-50,488 (a kappa agonist) decrease the locomotor
 
activity of adult rats and mice (Hayes, Skihgle, &
 
Tyers, 1985; Jackson & Cooper, 1985; Leighton, Johnson,
 
Meecham, Hill, & Hughes, 1987; Ukai & Kameyama, 1985;
 
Von Voightlander, Lahti, & Ludens, 1983). In contrast,
 
high doses of U-50,488 increase the locomotor activity
 
and wa11-climbing pf preweanling rats (Bolanos, Garmsen,
 
Glair, McPougall, & Crawford, 1995; Jackson & Kitchen,
 
1989). ' V M
 
Summarv and Proposal. When considered together it
 
appears that both the kappa opioid and DA systems induce
 
behavioral patterns which vary both quantitatively and
 
qualitatively across development. Curiously, kappa
 
opioid agonists and DA agonists have similar behavioral
 
effects in preweanling rats. This suggests that in the
 
these younger animals, kappa neurons may in some way
 
modulate those DA systems involved with unlearned
 
activity.
 
The purpose of this project was to assess the
 
possible interaction between the DA and kappa opioid
 
systems in the preweanling and adult rat. To this end,
 
17- and 80-day-old rats were treated with a variety of
 
direct and indirect DA agonists and antagonists, as well
 
as a kappa opioid agonist. Fos immunohistochemistry,
 
was used to identify those pathways activated by the
 
various drugs. This study should determine: first, the
 
behaviors elicited by kappa opioid and DA agonists in
 
both adult and preweanling rats; second, whether the
 
kappa and DA systems interact to mediate behavior; and
 
third, the neuroanatomical regions activated by kappa
 
and DA agonist treatment.
 
Dopamine Svstems
 
Dopamine Receptors. Dopamine receptors have been
 
classified into five structurally distinct receptor
 
subtypes: Di, D2, Da, D4, and Ds (Clark & White, 1987;
 
Sokoloff, Giros, Martes, Bouthenet, & Schwartz, 1990;
 
Sunahara et al 1991; Von Tol et al., 1991). Di and Da
 
receptors have been differentiated according to
 
behavioral effects, sensitivity to pharmacological
 
agents, anatomical locatiori, and effects on second
 
messenger systems (for a comprehensive review see Clark
 
& White, 1987). For example the Di receptor site
 
increases adenylyl cyclase g^ctiyity via a Gs protein;
 
whereas, the Da receptor site exerts an opposing
 
influence on adenylyl cyelase activity via a Gi protein
 
(Cooper, Bloom & Roth, 1991; Cunningham & Kelley, 1993).
 
Behavioral effects of dopamine agonists and
 
antagonists in adult rats. DA agpiiists are typically
 
classified as being either direct or indirect agonists.
 
Direct DA agonists [e.g., R-propyInorapomorphine (NPA)
 
and apomorphinel bind to the posf syhaptic recejpfbr and
 
mimic the endogenous neurotransmitter. Indirect DA
 
agonists (e.g.j amphetamine and cocaine) increase the
 
amount of synaptic DA in a number of different ways/
 
For example, cocaine blocks the reuptake of DA from the
 
synapse; whefeas, amphetamine increases DA release into
 
the synapse (Cooper et al., 1991).
 
Behavioral responses to DA agonists include, but
 
are not limited to, locomotion, sniffing, rearing, and
 
chewing (Arnt, 1987; Clark & White 1987). Utilization
 
of selective DA receptor agonists has revealed receptor-

specific behayibral profiles, bi agonists primarily
 
enhance grooming^^nd non-steredtyped locomotor activity;
 
whereas, D2 receptor stimulation enhances Tocorao
 
activity, rearing, head-down sniffing, and a variety of
 
oral movements (Arnt, Hyttel, & Perregaard, 1987;
 
Dall'Olio, Gandolfi, Vaccheri, Roncada, & Montanaro,
 
1988; Molloy & Waddington, 1985). The occurrence of
 
these behaviors is largely determined by dose, as a low
 
dose of nPa induces locomptor activity and rearing,
 
while a moderate dose preferentiariy induces head-down
 
sniffing. Oral behaviors, like chewing, licking, and
 
biting, only occur after higher doses of NPA or
 
apomorphine (Bordi, Carr, & Meller, 1989; McDOugall,
 
Crawford, & Nonneman, 1993; Mestlin & McDougall, 1993).
 
Interestingly, although these behaviors are thought to
 
be primarily Dz-mediated, they are only observed when
 
both Di and D2 receptors are activated (Barone, Davis,
 
Braun & Chase, 1986; Longini, Spina & Di Chiara, 1987;
 
Molloy & Waddington, 1985; Robertson & Robertson, 1986).
 
Thus, substantial activation of both Di and D2 receptors
 
is required to produce full expression of highly
 
stereotyped behaviors like licking and chewing.
 
Not surprisingly, selective or mixed DA antagonists
 
can either partially or completely block DA mediated
 
behavior. For example, SCH 23390 (a selective Di
 
receptor antagonist) inhibits grooming induced by the
 
selective Di agonist SKF 38393; whereas, sulpiride (a
 
selective Da receptor antagGnist) attenuates NPA-induced
 
locomotor activity, rearing, and sniffing (Arnt, 1987;
 
Clark & White, 1987). Interestingly, Di receptor
 
blockade also antagonizes the enhanced locomotor
 
activity, reariiig, and sniffing induced: by; Da^ agonists
 
(Arnt, 1987; Longoni et al., 1987). Additionally, the
 
Di agonist SKF 38393 intensifies or enhances some
 
behaviors induced by the Da agonist quinpirple
 
(Mashurano & Waddington, 1989; Robertson & Robertson,
 
1986). This DA receptor synergism suggests that either
 
a tonic level of Di activity is required for the
 
expression of Da-mediated behaviors ^ or the Da system
 
modulates the expression of behaviors initiated by the
 
Di system (Braun & Chase, 1986; McDougal1 et al., 1990;
 
Molloy & Waddington, 1985; Robertson & Robertson, 1986).
 
The ability of DA antagonists to attenuate or block
 
the effects of DA agonists has been discussed; however,
 
DA antagonists are also capable of eliciting their own
 
behavipral effects. DA receptor antagonists produce
 
catalepsy in rats. For example, SCH 23390 and YM-09151
 
(selective Di and D2 antagonists, respectively) produce
 
a dose-dependant increase in catalepsy in adult rats
 
(Christensen, Arnt, Hyttel, Larsen, & Svendsen, 19841
 
Terai, Usuda, Kuroiwa, Noshiro, & Maneno, 1983;
 
Wanibuchi & Usuda, 1990). Furthermore, antagonists that
 
block both Di and D2 receptors (e.g., haloperidol and
 
flupenthixol) most potently induce catalepsy (Verma &
 
Kulkarnij 1992; Wanibuchi & Usuda, 1990).
 
Behavioral effects of dopamine agonists and
 
antagonists in preweanling rats. In general,
 
preweanling rats exhibit adult-like behavior patterns
 
wheri treated with direct and indirect DA agonists. Like
 
adult rats, preweanling rats display increased rearing
 
and locomotor activity after acute treatment with the
 
indirect DA agonists amphetamine and cocaine (Barrett,
 
Gaza, spear, &•Spear, 1982; Campbell, Lytle, & Fibiger,
 
1969; Shalaby & Spear 1980). Similarly, nonselective
 
direct DA agonists (e.g., apomorphine and NPA) enhance
 
locomotor activity and sniffing in both the preweanling
 
and adult rat (Arnt, 1987; Mestlin & McDougall, 1993;
 
Shalaby & Spear, 1980). Preweanling rats, in general,
 
also display adult-like behavioral responses after
 
treatment with selective DA agonists. For example, SKF
 
38393 (a selective Di agonist) increases locomotor
 
activity in both 3- and 21-day-old rats, with increased
 
sniffing evident in slightly older rats. Although the
 
complete Da agonist behavioral profile (i.e., locomotor
 
activity, rearing, and sniffing) is not observed until
 
at least 21 days of age, quinpirole (a selective Da
 
agonist) enhances locomotor activity at all ages (Eilam
 
& Szechtman, 1989; Moody & Spear^ 1992; Walters &
 
Howard, 1990). Occasionally, DA agonists will produce
 
some age-dependant behavioral effects, however they are
 
often due to the maturation of motoric ability and not
 
because of qualitative changes in dopaminergic
 
functioning.
 
As with adult rats, the Di and D2 receptofs of
 
preweanling rats interact when mediating some behaviors,
 
however the specific behaviors showing synergism often
 
vary between preweanling and adult rats. For example,
 
co-administration of Di and D2 agonists (i.e., SKF 38393
 
and quinpirole) in 10-day-old rats induces a significant
 
decrease in mouthing; whereas, 21-day-old rats show
 
stereotyped licking after combined agonist treatment
 
(Moody & Spear, 1992). Similarly, 3- and 10-day-old
 
rats exhibit synergistic increases in DA agonist-induced
 
wall climbing and locomotor activity, while they fail to
 
show stereotyped oral movements. Therefore, the Di and
 
D2 receptors of preweanling rats appear to interact when
 
mediating some behaviors, however, the specific
 
behaviors showing D1/D2 synergism vary according to age.
 
Studies using DA antagonists also suggest that the
 
DA receptor systems of young and adult rats are
 
generally similar. For example, the quinpirole-induced
 
locomotor activity of preweanling rats is antagonized by
 
either SCH 23390 or sulpiride (Di and D2 antagonists,
 
respectively), while SKF 38393-induced grooming is
 
blocked by SCH 23390 (McDougall et al., 1990). In
 
addition, selective Di and D2 antagonists induce adult
 
like catalepsy in the preweanling rat, with the most
 
intense catalepsy being induced by joint D1/D2
 
antagonist treatment (Baez, Burt, Granneman, & Shanklin,
 
1979; Fitzgerald & Hannigan, 1989).
 
To summarize, preweanling and adult rats display
 
similar patterns of behavioral responding after DA
 
agonist and antagonist treatment. In general, DA
 
receptor activation elicits locomotor activity and
 
rearing, with more stereotyped behayiors, such as
 
sniffing, chewing, and biting, occurring when higher
 
doses of a DA agonist are used. Furthermpre, DA
 
antagonists produce a dose-dependant decline in DA
 
mediated behaviors, with catalepsy occurring at higher
 
doses (Arnt, 1987; Baez et al., 1979; Clark & White,
 
1987).
 
Opiate Systems
 
Qpioid Receptors. Opioid receptors have been
 
classified into three structurally distinct receptor
 
subtypes: mu, delta, and kappa (Lord, Waterfield,
 
Hughes, & Kosterlitz, 1977; Martin, Fades, Thompson,
 
Huppler, & Gilbert, 1976). Mu and delta receptors have
 
been differentiated according to pharmacological action
 
(Gilbert & Martin, 1976; Martin et al., 1976; Wollemann,
 
Benyhe, & Simon, 1993). For example, receptor binding
 
studies have revealed that morphine possesses high
 
affinity for mu feceptors; whereas^ delta receptors are
 
activated by enkfephalins (Brady &Holtzman, 1981;
 
Wolleraann et al. i 1993). Pharmacological Studies have
 
shown that kappaireceptors are different from mu and
 
delta receptors, i and they have been divided into three
 
distinct subclasses: kappai, kappa2, and kappas
 
receptors (Wollemannet al., 1993). More specifically,
 
kappai Sites havfe a high affinity for benzeneacetaminde
 
compounds (like |U^50,488); whereas, kappaa and kappas
 
sites display little affinity for U-50,488 (Wollemann et
 
al., 1993).
 
The various opiate receptor subtypes can also be
 
distinguished by; their behavioral effects. It is known
 
that mu agonists (e.g., DAGO and morphine) are involved
 
in pain modulation and activate reward processes;
 
whereas, kappa agonists (e.jg., tifluadom, bermazocine,
 
and U-50,488) reduce the spontaneous behavior of rats,
 
and appear to have aversive effects when tested in the
 
self-administration paradigm (Di Chiara & Imperato,
 
1988; Mucha & Herz, 1985; Yaksh, 1986). Evidence
 
suggests that opiate receptor activation plays a largely
 
modulatory role in behavior. In general, opiate
 
receptor agonists inhibit the release of other
 
neurotransmitters. Mu and delta agonists inhibit
 
release of coftical noradrenaline and striatal
 
acetylcholine; whereas, kappa receptor activation
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inhibits dopamine release in the striatum and cortex
 
(Wollemann et al., 1993).
 
Behavioral effects of mu and delta opioid agonists
 
and antagonists in adult and preweanling rats. In
 
general, mu receptor activation modulates pain and
 
reward system functioning; however, the unlearned motor
 
behaviors are affected as well. In adult rats,
 
increased lopomotor activity occurs after low doses of
 
morphine (1-2 mg/kg); whereas, higher doses (5-20 mg/kg)
 
induce behavioral depression, including reduced
 
locomotor activity and catalepsy (Brady & Holtzman,
 
1981; Fog, 1972). In contrast, morphine and DAGO (mu
 
agonists) have only cataleptic and sedative effects in
 
the preweanling rat (Bolanos et al., 1995; Caza & Spear,
 
1982; Jackson & Kitchen, 1989; Katz, 1984).
 
Behavioral responses to delta agonists also vary
 
across ontogeny. Treatment with low doses of DPDPE (a
 
delta agonist) increases the locomotor activity,
 
rearing, and sniffing of adult rats; whereas, higher
 
doses ipduce behavioral deprpssion (Cowan, Ranee, &
 
Blackburn, 1986; Cowan, Zhu, & Porreca, 1985). In
 
contrast, DPDPE does not affect the behaviors of
 
preweanling rats (Jackson & Kitchen, 1989). In summary,
 
agonists at the mu and delta opiate receptor have
 
pronounced age-dependent behavioral actions in
 
preweanling and adult rats.
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Behavioral effects of kappa OTaioid agonists and
 
antagonists in adult rats. Kappa agonists induce
 
conditioned place aversions and taste aversions in adult
 
animals (Bechara & Van der Kooy, 1987; Mucha & Herz,
 
1985), The aversive properties of U-50,488 are mediated
 
at both the peripheral and central level, with the
 
central- effects possibly resulting from decreased DA
 
release within the nucleus accumbens (Bals-Kubic, Herz,
 
& Shippenberg, 1989; Bechara & Van der Kooy, 1987; Di
 
Chiara & Imperato, 1988). Kappa receptor activation
 
alsp affects Unlearned behaviors, In both rats and
 
mice, decreased locomotor activity follows treatment
 
with U-50,488, tifluadom, and bermazocine (Castellano &
 
Pavone, 1987; Crawford, McDougaTl, Bolanos, Hall, &
 
Berger, 1995; Hi Chiara & impeirato, 1988; Friyette &
 
Terrian, 1995; Von Voightlander et al., 1983)^
 
Interestingly, kappa agonists elicit a dose-dependant
 
behavioral depression similar to that mediated by DA
 
antagonists. For example, U-50,488 (5 or 10 mg/kg,
 
s.c.) attenuates the locomotor activity of adult rats;
 
whereas, catalepsy follows higher doses of the kappa
 
agonist (Jackson & Cooper, 1985; Ukai & Kameyama, 1985;
 
Von Voightlander et al., 1983).
 
Further evidence for the role of the kappa receptor
 
in behavior is provided by studies using the selective
 
kappa antagonists binaltorphimine and nor­
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binaltorphimine (nor-BNI). Although these compounds
 
have only recently been developed, it has been shown
 
that U-50,488-induced catalepsy and antinociception are
 
blocked by hor-BNI {Jones & Holtzman, 1992). The later
 
results are important, because they clearly indicate
 
that U-50,488 is affecting behavior by Acting at the
 
kappa receptor. In suminary, the kappa opioid systems
 
ability to decrease DA release inhibits unlearned
 
activity, and the mediation of conditioned place
 
aversion and taste aversion in adult rats (Bechara & Van
 
der Kooy, 1987; Carr, Bak, Simon, & Portoghese, 1989;
 
Crawford et al., 1995).
 
Behavioral effects of kappa opioid agonists and
 
antagonists in preweanling rats. In direct contrast to
 
adults, the kappa agonist U-50,488 elicits a dose-

dependent increase in the locomotor activity of the
 
preweanling rat (Bolanos et al., 1995; Jackson &
 
Kitchen, 1989; Kehoe & Boylan, 1994). Furthermore,
 
kappa agonists, like DA agonists, elicit age- and dose­
dependant behavioral responding in the fetal and
 
preweanling rut. For example, U-50,488 promotes dCse­
dependant increases in the activity of the fetal rat by
 
as early as day 21 of gestation (Smotherman, Moody,
 
Spear, & Robinson, 1993). In 5- and 10-day-old rats U­
50,488 (0.1 and 1.0 mg/kg) preferentially enhances
 
locomotor activity and wall-climbing; whereas, wal1­
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climbing predominates in the 20-day-C)ld {Jackson &
 
Kitchen, 1989). Dbse is an important constraint on U­
50,488's effects, as 10 mg/kg U-^50,488 initially sedates
 
the 20-day-old rat, with wall-climibing and locomotor
 
activity emerging as the drug wears off (Birch & Hayes,
 
1987; Jackson & Kitchen, 1989).
 
The paradoxical effects of the kappa agonists in
 
the preweanling rat, however, appear to be confined to
 
increased locomotor activity. Similar to adult rats,
 
kappa opiates produce an analgesic effdct in pireweanling
 
rats (Barr, 1992; Barr, Paredes, Erickson, & Zukinj
 
1986). Furthermore, 3- and 7-day-old rats given U­
50,488 display,Cbnditi piace aversions like aduIt
 
rats (Barr, Wang, & Garden, 1994). These findings
 
indicate tha:t the analgesic and aversive properties of
 
the kappa agonists are similar in adult and preweanling
 
rats. Moreover, these resnlts suggest that U-50,488's
 
locomotor activating effects in the preweanling rat are
 
not caused by the aversive effects of this drug (Barr et
 
al., 1994; Garden, Barr, & Hofer, 1991).
 
The role of kappa receptors in mediating the
 
behavioral responses of preweanling rats was confirmed
 
using nor-BNI (a kappa antagonist). For example, U-

50,488-induced analgesia and locomotor activity are
 
blocked by nor-BNI (Jackson & Kitchen, 1989; Kehoe &
 
BoyIan, 1994). In contrast, selective mu or delta
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antagonists (e.g., M8008 and ICI 174,864, respectively)
 
do not affect the activity enhancing actions of U-50,488
 
in the preweanling rat (Birch & Hayes, 1987).
 
Interestingly, treatment with SCH 23390 (a selective Di
 
receptor antagonist) fails to inhibit the fetal motor
 
behavior produced by U-50,488 (Smotherman et al., 1993).
 
However, the kappa antagonist nor-BNI effectively blocks
 
both U-50,488- and SKF 38393-induced motor activity in
 
the fetal rat (Smotherman et al., 1993). This suggests
 
that fetal motor behaviors are initially mediated by the
 
kappa receptor, with the DA system only modulating kappa
 
functioning (Robinson, Moody, Spear, & Smotherman, 1993;
 
Smotherman et al., 1993). This DA-to-opioid interaction
 
differs from the typical opioid-to-DA pattern reported
 
in adult studies (DeVries, Hogenboom, Mulder, &
 
Schoffelmeer, 1990; Mulder, Wardeh, Hogenboom, &
 
Frankhuyzen, 1984; Schoffelmeer et al., 1988). This may
 
reflect differences in experimental methodology, or may
 
indicate ontogenetic changes in the relationship between
 
the kappa opioid and DA systems (Smotherman et al.,
 
1993). If the latter is correct, developmental
 
differences could be mediated by changes in the
 
distribution of kappa opioid receptors within the CNS
 
(Smotherman et al., 1993).
 
In summary, although the behavioral responses
 
elicited by kappa opioid agonists in adult rats have
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been well documented, there has been relatively little
 
examination of the behavioral effects of these drugs in
 
the preweanling rat. Even so, kappa agonists do appear
 
to produce pronounced age-dependant effects in the
 
preweanling and adult rat. Kappa agonists inhibit
 
behavioral responding in the adult; whereas, these same,
 
drugs enhance behavioral activity, including locomotion
 
and wall climbing, in the preweanling rat (Bolanos et
 
al., 1995; Jackson & Kitchen, 1989; Locke & Holtzman,
 
1986; Smotherman et al., 1993). Importantly, the
 
pattern of these behavioral responses provides further
 
evidence that the kappa opiate and DA systems interact
 
to mediate behavior.
 
Dopamine Pathways
 
The dopaminergic system is highly organized
 
topographically. On the basis of their efferent
 
projections, dopaminergic cell groups have been broadly
 
classified into two groups: (1) the mesolimbic­
mesocortical pathway and (2) the nigrostriatal pathway
 
(Cooper et al., 1991; Role & Kelly, 1991).
 
Mesolimbic-mesocortical pathway. DA fiber
 
projections making up the mesolimbic-mesocortical
 
pathway have their cell bodies in the ventral tegmental
 
area (VTA). The cells of the mesolimbic component of
 
this pathway project from the VTA to the limbic system,
 
primarily the nucleus accumbens (Cooper et al., 1991;
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Koob, 1992)/ Recently) an p model has been
 
prpiposed to explain the interactions between the opiate
 
and DA systerns (see Figure 1) (Di Chiara & North, 1992;
 
Spanagel, Herz, & Shippenberg, 1992). Two opposing
 
opipid systems, located in different parts of the
 
mesolimbic system, modulate DA neurons projecting to th
 
nacleus aCCumbens. Mu receptors located on GABA
 
inhibitbry heurOns in the VTA disinhibit DA neurons
 
projecting to the nucleus accumbens. Thus, the mu-

induced reduction of GABA^fflediated Inhibition
 
facilitates DA release in the nucleus accumbens. in
 
contrast, kappa receptors, located on DA terfflinals in
 
the nucieus acCumbens, inhibit DA release. The opposing
 
actions of the two opioid systems assist in the
 
maintenance Of basal DA rbiease in the nucleus accumbens
 
(Di Chiara & North, 1992; Spanagelet al., 1992). This
 
model, and the evidence supporting it, suggests that the
 
kappa opioid system plays an ifflportant role in
 
mpdulatirtg DA input, particularly in the nucleus
 
. accumbens-..
 
Behavioral evidence generally supports this
 
kappa/DA model. For example,fflicroinjections of d-

amphetamine into the nucleus accu®®hens produces
 
locomotor activity in adult rats (Colle & Wise, 1991).
 
Further, injections of NPA into the nucleus accumbens
 
results in a dose-dependant increase in oral behaviors
 
17
 
and sniffing (Bordi et al., 1989). Although
 
microinjection studies using kappa agonists have not yet
 
ijeen reported, systdinic treatment with U-50,488
 
pfesumahly depresses the locomotor activity of ddult
 
rats by decreasing DA release in the nucleus accumbens
 
(Crawford et al., 1995; Di Chiara & Imperato, 1988).
 
Consistent with this, kappa agonists reduce, and kappa
 
antagonists increase, DA release in the aCcumbens (Di
 
Chiara & Imperato, 1988; Spanagel et al., 1992).
 
Nigrostriatal pathwav. The nigrostriatal pathway
 
originates in the substantia nigra and projects
 
primarily to the striatum, composed of the putamen and
 
caudate nucleus (Nolte, 1981). The substantia nigra,
 
which lies in the midbrain, has two zones: the pars
 
reticulata and the pars compacta. Receptor binding
 
studies indicate that large amounts of opiate receptors
 
(mu and kappa) are present in the pars compacta, with
 
low levels present in the pars reticulata (Matsumoto,
 
Brinsfield, Patrick, & Walker, 1988; Merchenthaler,
 
Maderdrut, Altschuler, & Petrusz, 1986). Evidence
 
suggests that kappa opioid agonists have dual opposing
 
effects on activity: a motor activating effect mediated
 
by nondopaminergic pars reticulata cells and a motor
 
inhibitory effect mediated through the pars compacta DA
 
cells (Matsumoto et al., 1988). For example, treatment
 
v/ith U-50,488 reduces locomotor activity by decreasing
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the firing rhte of dopamine cells in the shhstantia
 
nigria fWalker j /fhoiHpsoh, Frascella, & Frederick, 1987) C :
 
and by decreasing the release of dopamine in the
 
striatuiB (iHJperato & Di Chiara, 1985).
 
Micrbiajections of DA agonists directly into the
 
striatuin produce a wide ranga of behavioral respohses•
 
Episodes Of DA-m^^ loeomotor activity, rearing, and
 
grooming follow iRjections of low doses of NPA into the
 
siriatam (Bordi et al., 1989). Furthermore, injections
 
Of NPA of apomorphine into the striatum also enhances
 
sterOOtyped: sniffing and oral behaviors. At doses from
 
5.0^20 JUg a linear increase in both behaviors is
 
evident; whereas, at higher doses (40>tg> the increased
 
receptor occupancy results in stereotyped behavior,
 
comprised of enhanced oral behaviors accompanied by a
 
decrease in sniffing {Bprdi et al., 1989; Scheel-Kruger
 
& Afnt, 1985). Furthermore, microinjections of U-50,488
 
into the Substantia nigra pars reticuiata elicits long­
dufation rotational behavior (Matsumoto et a1., 1988).
 
These findings suggest that kappa opiate receptors
 
1ocated in the nigrostr1atal pathway are invo1ved in the
 
regulation of DA-mediated skjtor function. This evidence
 
indicates that opiate receptor agonista elicit
 
behavioral respdnses by activatihg both the mesolimbic­
mesocortical and nigrostriatal pathways (Matsumoto et
 
al., 1988). . , /y
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In suHJmary j DA pathw^ are both topographieaily
 
and bebayiorally dissbciable. The fflesoliffibiG­
mesoeortieal pathway prpjeets the ventral tegmental
 
area to linibio and CGrtical regiGns and appears to be
 
neeessary for a nuHiber of DA-mediated behayiors. The
 
nigtostriatal pathway projects froia thb snbstantia higra
 
to several striatal regions and is most eritieally
 
involved in mediating stereGtyped behaviGr, Evidence
 
shows that kappa opiate receptors are present and active
 
in both pathways, affecting behavior by fflodulating DA
 
"' .•rel.ease'i, ,
 
Fos Immiinohistochemistrv. Fos immunohistochemistry
 
is a new techniqne w^^ ideally suited for
 
determining the pfecise location of heuronal activation.
 
Various DA-^acting drugs elieit the trahsient expression
 
of Fos, the p^ the early response gene e-/bs
 
{DragunGw, RGd>ertsGn, Fauil, Robertson, & Jansen, 199G;
 
Graybiel, Moratalla, & Robertson, i99D). Therefore, Fes
 
expression reflects neuronal activity in the CNS
 
(Miller, 1990; Sagar, Sharp, & Curran, 1988). Following
 
treatment with amphetamine, enhanced locomotor activit^^^^^^^
 
is accompanied by extensive c-fos induction in the
 
medial two-thirds of the striatum, as well as the
 
nucleus accumbens, olfactory tubercles, and a variety of
 
other brain regions (Bullitt, 1990; Graybiel et al.,
 
1990; Sharp, Gonazales, Sharp, & Sagar, 1989; Snyder­
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Keller, 1991; Torres & Rivier, 1994). Likewise, cocaine
 
produces large increases in striatal c-fos expression,
 
which is potently blocked by the selective Di receptor
 
antagonist SCH 23390 (Carney, Tolliver, Carney, & Kindy^,^^^^
 
1991; Dragunow et al., 1990). Utilizat o
 
immunohistochemiStry fG1Ipwin administration of thb
 
kappa agonist U-50,488 should elucidate the specific
 
brain areas involved in the opioid activation of
 
behavior.
 
Kappa/Dopamine Interactions
 
Behavioral and pharmacological evidence suggests
 
that kappa raceptors may affect behavior by modulating
 
the functioning of DA neurons. Consistent with this,
 
Crawford et al. (1995) have shown that the kappa opioid
 
agonist U-50,488 antagonizes cocaine-induced locomotor
 
activity in adult rats. This indicates that kappa
 
neurons moduiatP those DA systems involved in unlearned
 
activity. cocaine-induced Fos
 
imraunoreactivity in the adult rat is blocked by U-50,488
 
pretreatment, further indicating that the DA and kappa
 
opioid systems interact (Crawford et al., 1995).
 
In summary, behavioral studies indicate that there
 
is a substantial ontogenetic change in the way that the
 
kappa and DA systems iat^^^ to mediate behavior. More
 
specifically, U-50,488 the loeomptor activity
 
of prewbanling rats, while decreasing the locomotor
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activity of adult rats (Bolanos et al., 1995; Jackson &
 
Kitchen, 1989; Kehoe & Boylan, 1994; Sniotheraian et al.,
 
1993). In adults, the U-50,488-induced decrease in
 
locoBiotor activity is presumably due to the modulation
 
of DA functioning in the substantia nigra and/or nucleus
 
accumbens; however, the neurobiological mechanisms
 
underlying U-50,488's behavioral activating effects in
 
preweanling rats is entirely unknown. Interestingly,
 
the locomotor activating effects of kappa and DA
 
agonists are similar in the preweanling rat, suggesting
 
that kappa neurons may, in some way, modulate those DA
 
systems involved with unlearned activity. The present
 
study further examined this kappa/DA interaction in
 
order to elucidate the mechanisms involved in the kappa-

mediated behaviors of preweanling rats.
 
This project assessed the possible interaction
 
between the DA and kappa opioid systems in the
 
preweanling rat. A total of six hypotheses were
 
proposed: (1) I proposed that the kappa agonist U­
50,488 would decrease locomotor activity in the adult
 
rat: a result that has been reported previously
 
(Crawford et al., 1995); (2) As previously shown, U­
50,488 was expected to increase the locomotor activity
 
of the preweanling rat (Bolanos et al., 1995; Jackson &
 
Kitchen, 1989; Kehoe & Boylan, 1994); (3) U-50,488 was
 
expected to potentiate amphetamine- and NPA-induced
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locomotor activity and sniffing. This w
 
that U-50,488 and the DA agonists are inodhlating
 
behavior by affecting the same nebroahatofiiical pathways;
 
(4) Flupenthixol (a nonSelective DA receptor antagonist)
 
was predicted to redpce U-5G,488-mediated iocQmoto^^
 
activity. This would indicate that the behaviors
 
elicited by this agonist are ultimately DA mediated; (5)
 
Amphetamine and NPA would induce regional expressibn of
 
FOS immunoreactiVity in the preweanling rat: an
 
observation pbserved in adult rats, but hot tested in
 
preweaniing rats (hdbbrtspn, Petersoni Murphy, &
 
Robertson, 1989; Snyder-Keller, 1991); (6) U-50,4S8-,
 
amphetamine-, and NPA-mediated Fos immunoreactivity was
 
predicted to occur in the same brain regions. This
 
would pinpoint those brain areas involved in unlearned
 
activity; moreoyer, it would indicate that the kappa and
 
DA agonists are affecting the same pathways.
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FIGURE CAPTION
 
Figure 1. Proposed model for the modulation of DA
 
neurons by opposing tonically active endogenous opioid
 
systems. In the ventral tegmental area a tonically
 
active mu opioid system stimulates the DA neurons via
 
disinhibition of the GABA-containing interneuron. In
 
the nucleus accumbens a tonically inhibitory kappa
 
opioid system suppresses the release of DA by AlO
 
neurons. The action of both opioid systems is necessary
 
for the maintenance of basal DA release.
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General Method
 
Subiects . ■ 
Subjects were 248 male and 248 female Sprague-

Dawiey rats (Harlan). Lltters were culled to 8 to 10
 
rat pups at three days of age. Rats were tested when
 
eithef 17 or 80 days of age. The 17-day-olds were
 
housed with the dam prior to behavioral testing. The
 
80-day-old rats were individually housed until the test
 
day. Assignment of male and fema1e rat pups was
 
counterbalanced, with no more than one rat from each
 
litter being placed into a particular group. The colony
 
room was maintained at 23-25oc and kept under a
 
14:10/L:D cycle. Behavioral testing was conducted
 
during the light phase of the cycle.
 
Apparatus
 
Behavioral testing was done in grey p1ywood
 
chambers (30 x 30 x 42 cm), with floods divided by lines
 
into four equdl quadrants.
 
Evaluation of behavioral testing
 
A single line-cross was scored when a rat's front
 
two paws completely crossed one of the lines dividing
 
the floor of the testing chamber. Line-crossing was
 
measured continuously across the testihg session,
 
whereas the Pecurrence of stereotyped (head-down)
 
sniffing was assessed every 20 s using a time sampling
 
procedure.
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Drugs
 
The drugs used were d-amphetamine sulfate
 
Chemieals, St. Louis, Mo.), i?-propyinorapomorphine
 
(NPA)i flupenthixol (Research
 
Biocheiriicais, Natick, Mass). All drugs were mixed in
 
saline at a volume of 5 ml/kg. U-50,488 was injected
 
subcutaneously (s.c.), whereas all other drugs were
 
injected intraperitoneally (i.p;).
 
Statistics
 
Analyses of variance (ANOVAs) were used for the
 
statistical analysis of both the behavioral and
 
immunohistochemistry data. For the locomotor activity
 
data repeated measures ANOVAs were performed across six
 
10-min time blocks; whereas, the sniffing data was
 
analyzed across two 30-min time blocks for the initial
 
four experiments. For the remaining experiments,
 
sniffing data was analyzed using repeated measures
 
ANOVAs across six 10-min time blocks.
 
Data from the Fos immunohistochemistry experiment
 
were analyzed using two-way ANOVAs (for each brain
 
region). When appropriate, Tukey tests (P<0.05) were
 
used for making post hoc comparisons. U-50,488 has been
 
shown to increase the locomotor activity of the
 
preweanling rat (Bolanos et al., 1995). Therefore, it
 
was predicted that U-50,488 would enhance Fos expression
 
in the 17-day-old rat, but not the adult rat. To
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analyze the effects of y-50,488 on Fos expression t-

tests (P<0.05) were used to compare U-50,488- and
 
saline-treated rats.
 
■ ' .■ Experiment--.''la' ' ­
The Behaviorai Effects of U-50,488, 
a Kappa Opioid Agbnisty in T7--Day-Old Rats 
Method j . 
Sublects, Thirty-two male arid female 17-day-old 
Sprague-Dawley albino rats (Harlan) werb used. 
Procedure. Four groups of 17-day-old rats (n= 8) 
received an acute injection of U-50,488 (0, 2, 5, or 10 
mg/kg) immediately prior to the behavioral testing 
session. Line-crosses and stereotyped (head-down) 
sniffing were assessed during a 60-min testing session 
by an observer blind to treatment conditions. 
Results ■■ ■ ;; 
Line-crosses. Overall, 17-day-old rats treated 
with U-50,488 (2.0, 5.0, 10.0 mg/kg) had significantly 
more line-crosses than saline controls (see Figure 2) 
[condition main ef fect ,v J^( 3 ,2 P<0 .001; and 
Tukey tests, P<0.05]. The total number of 1ine-crosses 
decreased across testing [time main effect, 
F{ 5,140)=8.68, P<0.001; and Tukey tests, P<0.05], 
During the initial testirig block, rats injected with 
10.0 mg/kg U-50,488 had significantly more line-crosses 
than rats given 2.0 mg/kg or 5.0 mg/kg U-50,488 
28 
[Condition X Time interaction, F(15,140)=3.82, P <0.001;
 
and Tukey tests, P <0.05]. However, for the remainder
 
of testing there were no significant differences between
 
U-50,488-treated rats.
 
Stereotyped sniffing. There were no significant
 
differences between 17-day-old rats injected with either
 
U-50,488 or saline (see Table 1).
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FIGURE CAPTION
 
Figure 2. Mean number of line-crosses during the 60-min
 
behavioral testing session. The 17-day-old rats (n = 8)
 
were injected with U-50,488 (2.0, 5.0, or 10.0 mg/kg,
 
s.c.) or saline immediately prior to behavioral testing.
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Table 1. Mean stereotyped sniffing counts (+SEM)' of 17­
day-old rats given U-50,488 (0.0--10.0 mg/kg).
 
Behavioral testing occurred immediately after U-50,488
 
treatment and was recorded for 60 min (divided into two
 
30-min testing periods).
 
Stereotyped Sniffing Counts
 
U-50,488 First 30 Min Second 30 Min
 
0.0 mg/kg 0.75 + 0.49 0.25 + 0.25
 
2.0 mg/kg 4.63 + 0.94 2.25 + 0.79
 
5.0 mg/kg 6.25 + 5.97 2.63 j- 2.63
 
10.0 mg/kg 0.88 0.49 1.50 + 0.59
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Experiment lb
 
The Behavioral Effects of Amphetamine,
 
an Indirect DA Agonist, in 17-Day-Old Rats
 
Method
 
Subjects. Thirty-two male and female 17-day-old
 
Sprague-Dawley albino rats (Harlan) were used.
 
Procedure. Four groups of 17-day-old rats (n = 8)
 
received an acute injection of amphetamine (0, 1, 2.5,
 
or 5 mg/kg) immediately prior to behavioral testing.
 
Line-crosses and stereotyped (head-down) sniffing were
 
assessed during a 60-min testing session by an observer
 
blind to treatment conditions.
 
Results
 
Line-crosses. Overall, rats given amphetamine had
 
significantly more line-crosses than rats receiving
 
saline (see Figure 3) [condition main effect,
 
F(3,28)=3.90, P<0.05; and Tukey tests, P<0.05]. The
 
total number of line-crosses decreased across testing
 
[time main effect, F(5,140)=19.01, F<0.001; and Tukey
 
tests, P<0.05]. Across the initial two testing blocks
 
rats receiving amphetamine had significantly more line-

crosses than the saline controls (see Figure 3)
 
[Condition X Time interaction, P(15,140)=2.17, P<0.01;
 
and Tukey tests, P<0.05]. However, only rats receiving
 
1.0 mg/kg amphetamine had significantly more line-

crosses than saline controls on each of the testing
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blocks [Tukey tests, P<0.05].
 
Stereotyped sniffing. Overall, rats given 5.0
 
mg/kg amphetamine had significantly more stereotyped
 
sniffing counts than saline-treated rats {see Table 2)
 
[condition effeet, F(3,28)=4.15, P<0.05; and Tukey
 
tests, F<0.05]. Rats receiving 1.0 and 2.5 mg/kg
 
amphetamine did not differ from the saline controls.
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FIGURE CAPTION
 
Figure 3. Mean number of line-crosses during the 60-min
 
behavioral testing session. The 17-day-old rats (n = 8)
 
were injected with amphetamine (1.0, 2.5, or 5.0 mg/kg,
 
i.p.) or saline immediately prior to behavioral testing.
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Table 2. Mean stereotyped sniffing cpuiits (+SEM) of 17­
day-old rats given amphetamine (0.0--5.0 nig/kg).
 
Behavioral testing occtirred iniinediately after treatinent
 
and was recorded for 60 min {divided into two 30-min
 
.testing ■,peripds)V "■ 
Stereotyped Sniffing Counts 
Amphetamine First 30 Min Seebnd 30 Miri 
0.0 mg/kg 0.50 +0,33 0.50 ± 0.38 
1.0 P 4.00+2.67 2;25 +1.14: 
2.5 mg/kg 1.50 ± 1.05 
5.0 ing/kg 12.00 + 4.74A 3.25 + 1.194 
ASignificaht cdndition main effect indicating that 
amphetamine-treated rats v/ere sigriifican11y different 
from the saline-treated rats, P<0.05. 
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Experiment Ic
 
The Behavioral Effects of NPA,
 
a Direct DA Agonist, in 17-Day-Old Rats
 
Method
 
Subiects. Thirty-two male and female 17-day-old
 
Sprague-Dawley albino rats (Harlan) were used.
 
Procedure. Four groups of 17-day-old rats (n = 8)
 
received an acute injection of NPA (0, 0.1, 0.3, or 1.0
 
mg/kg) immediately prior to behavioral testing. Line-

crosses and stereotyped (head-down) sniffing were
 
assessed during a 60-min testing session by an observer
 
blind to treatment conditions.
 
Results
 
Line-crosses. Overall, all of the NPA-treated
 
groups had significantly more line-crosses than the
 
saline group (see Figure 4) [condition main effect,
 
F(3,28)=16.74, P<0.001; and Tukey tests, P<0.05]. The
 
total number of line-crosses decreased across testing
 
[time main effect, P(5,140)=32.96, P<0.001; and Tukey
 
tests, P<0.05]. Rats given 0.3 and 1.0 mg/kg NPA had
 
significantly more line-crosses than the saline controls
 
on all of the testing blocks [Condition X Time
 
interaction, P(15,140)=3.25, P<0.001; and Tukey tests,
 
P<0.05]. The rats receiving 0.1 mg/kg NPA only differed
 
from the saline controls on the first two testing blocks
 
[Tukey tests, P<0.05].
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stereotyped sniffing. Overall, 17-day-old rats
 
injected with NPA had significantly more stereotyped
 
sniffing counts than saline controls (see Table 3)
 
[condition main effect, F(3,28)=16.74, i'<0.001; and
 
Tukey tests, P<0.05]. The differences between the NPA
 
and saline groups were apparent on both test periods
 
[Condition X Time interaction, F(3,28)=3.41, P<0.05; and
 
Tukey tests, P<0.05]. During the second testing period,
 
rats given 0.3 mg/kg NPA had significantly more sniffing
 
counts than all other groups [Tukey tests, P<0.05].
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FIGURE CAPTION
 
Figure 4. Mean number of line-crosses during the 60-min
 
behavioral testing session. The l7-day-old rats {n = 8)
 
were injected with NPA {G.l, 0.3, or 1.0 mg/kg, i.p.) or
 
saline immediately prior to behavioral testing.
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Table 3. Mean stereotyped sniffing counts (+SEM) of 17­
day-old rats given NPA (0.0--1.0 mg/kg). Behavioral
 
testing occurred immediately after NPA treatment and was
 
recorded for 60 min (divided into two 30-min testing
 
periods).
 
stereotyped Sniffing Counts
 
NPA First 30 Min Second 30 Min
 
0 i 0 mg/kg 1.12 0.44 0.00 0.00
 
0.1 mg/kg 32.75 +2.06^ 24.13 + 2.83^
 
0.3 mg/kg 38.13 + 6.18^ 44.75+ 5.63ab
 
1.0 mg/kg 38.50 + 5.45® 23.75 ±5.03®
 
®Significant Condition X Time interaction indicating
 
that rats given NPA had significantly more
 
stereotyped sniffing counts than saline-treated rats
 
during both testing periods, P<0.05.
 
^Significant Condition X Time interaction indicating
 
that the 0.3 mg/kg NPA group was significantly
 
different from all other groups during the final 30­
min testing period, P<0,05.
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Experiment Id
 
The Behavioral Effects of U-50,488,
 
a Kappa Opioid Agonist, in 80-Day-Old Rats
 
Method
 
Subjects. Thirty-two male and female 80-day-old
 
Sprague-Dawley albino rats (Harlan) were used.
 
Procedure. Four groups of 80-day-old rats {n = 8)
 
received an acute injection of U-50,488 (0, 2, 5, or 10
 
mg/kg) immediately prior to behavioral testing. Line-

crosses and stereotyped (head-down) sniffing were
 
assessed during a 60-min testing session by an observer
 
blind to treatment conditions.
 
Results
 
Line-crosses. Overall, rats given 2.0 mg/kg U­
50,488 had significantly more line-crosses than rats
 
receiving saline (see Figure 5) [conditiCn main effect,
 
F(3,28)=3.63, P<0.05; and Tukey tests, P<0.05]. There
 
was a rapid decline in the total number of line-crosses
 
across testing [time main effect, P(5,140)=107.18,
 
P<0.001; and Tukey tests, P<0.051. For example, from
 
the first to second testing block, there was a
 
significant decrease in line-crosses of rats given 10.0
 
mg/kg U-50,488 [Condition X Time interaction,
 
P(15,140)=3.26, P<0.001* and Tukey tests, iP<0.05]. Rats
 
given 2.0 mg/kg U-50,488 had significantly more line-

crosses than saline- and 10 mg/kg U-50,488-treated rats
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during the second testing block [Tukey tests, i'<0.05].
 
There were no significant differences betv/een U-50,488­
and saline-treated rats during the fourth and fifth
 
testing blocks. During the final testing block, rats
 
given 10.0 mg/kg U-50,488 had significantly more line-

crosses than saline-treated rats [Tukey tests, P<0.05].
 
Stereotyped sniffing. Overall, the total number of
 
sniffs declined from the first to the second testing
 
period (see Table 4) [time main effect, F(1,28)=75.81,
 
i'<0.001]. There were no significant differences in
 
sniffing counts between saline- or U-50,488-treated
 
rats.
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FIGURE CAPTION
 
Figure 5. Mean number of line-crosses during the dO-min
 
behavioral testing session. The 80-day-old rats {n = 8)
 
were injected with U-50,488 (2.0, 5.0, or 10.0 mg/kg,
 
s.c.) or saline immediately prior to behavioral testing.
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Table 4. Mean stereotyped sniffing counts (+SEM) of 80­
day-old rats given U-50,488 (0.0--10.0 mg/kg).
 
Behavioral testing occurred immediately after U-50,488
 
treatriient and was recorded for 60 min (divided into two
 
30-min testing periods).
 
Stereotyped Sniffing Counts
 
U-50, First 30 Min Second 30 Min
 
mg/kg 2.75 + 0.86 2.25 + 0.61A
 
2.0 mg/kg 4.25 ± 0.82 4.25 + 0.92A
 
5.0 mg/kg 4;t3 + 0.63 4.00 ±0.65A
 
10.0 mg/kg 6.25 + 0.12 :5'-:25,7-±;pv';5:2:^^
 
^Significant time main effect indicating that the total
 
number of s counts in the second 30-min
 
testing period was significant1y different from the
 
first 30-min testing period, P<0.05.
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Discussion
 
Results showed that U-5Dj4B8-treatment dtafflatically
 
increased the locomotor activity of i7-day-^oid rats.
 
However, U-50,488 had no effect on the stereotyped
 
sniffing of preweaniing rats. In the 17-day-'c5ld rat 5.0
 
mg/kg U-5Q,488 prodticed a consistent level of loeomotor
 
activity across the testing session. In SOr-day-old
 
rats, 5.0 mg/kg U-50,488 produced a rapid deeiine in
 
locomotor activity, while having no effect on
 
stereotyped sniffing. lased on these reSuIts the 5.0
 
mg/kg dose of U-50,488 was used in subsequent
 
All doses of amphetaraine and NPA increased the
 
loComotor activity of l7-day-Gld rats. Importantly,
 
high doses of a DA agonist can induce stereotypical
 
behavior in the rat, often masking a drug's locomotor
 
activating effects. Therefore, based on these results
 
2.5 mg/kg amphetamine and i.O mg/kg NPA were used for
 
future experiments.
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.(
 
 Experiment' 2 ■
 
The Effects of the DA Antagonist
 
on U^50,48S-Induced Behavior&
 
; . in' ■ r,'
'!7-Day-Old'-Rats 

This experiment was designed to determine whether
 
U-5G,488 works threugh a dopaminergic mechanise. More
 
specificaliy, if flapenthixol blocked U-50,488's
 
behavioral effects it would suggest that U^SO,488
 
increases activity by enhancing DA funetionihgi
 
Method
 
Subjects. Forty-bight male and female 17-day-old
 
Sprague-Dawley albino rats {HarIan) were used.
 
Procedure. Six groups of l7-day-old rat rats (n =
 
8) received an acute injection of the dopamine receptor
 
antagonist flupenthixol (0, 0.025, 0.1, 0.4, or 0.8
 
mg/kg) 30 min prior to behavioral testing. The same
 
rats then received U-50,488, NPA, or amphetamine
 
immediately prior to a 60-min behavioral testing
 
session.,, ^
 
Results
 
Line-crosses. pverall, rats pretreated with 0.4 or
 
0.8 mg/kg flupenthixol had significahtly fewer 1ine­
crosses than salihe-pretreated rats (ise^ Fig^^
 
[Condition main effect, F(4,35)=37.43, P<0.001; and
 
Tukey tests^ P<0.05]. Pretreatment with 0.8 mg/kg
 
flupenthixol significantly reduced U-50,4S8-induced
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loconlotor activity on each of the testing blocks
 
[Condition X Time interaction, F(20,175)=4.48, P<0.001;
 
and Tukey tests, P<0.05]. Furthermore, pretreatment
 
with 0.4 mg/kg flupenthixol attenuated U-50,488-induced
 
locomotor activity across the last four testing blocks
 
[Tukey tests, P<0.05], Neither 0.025 or 0.1 mg/kg
 
flupenthixol had any significant effects on U-50,488­
induced locomotor activity.
 
Stereotyped sniffing. Overall, the total number of
 
sniffing counts declined from the first to second 30-min
 
testing period (see Table 5) [time main effect,
 
F(1,35)=15.31, P<0.05]. However, there were no
 
significant differences due to condition.
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FIGURE/CAPTION, ■ 
Figure 6. Mean number of line-crosses during the 60-min 
behavioral testing session. The 17^day-6ld hats {n = 8) 
were injec;ted with flupenthixol (0.025, 0.1, 0.4, or 0.8 
mg/kg, i.p.) 60 min prior to behayipral testing. Rats
 
were then given U^50,488 (5.0 mg/kg, s.c.), amphetamine
 
(2.5 mg/kg, i.p;), NPA (1.0 siig/kg, i -P.) or saline
 
immediately prior to testing.
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Table 5. Mean stereotyped sniffing counts (+SEM) of 17­
day-old rats given U-50,488 (5.0 mg/kg) 30 min after
 
treatment with flupenthixol (0.0—0.8 mg/kg). !<
 
Behavioral testing occurred immediately after U-50,488
 
treatment and was recorded for 60 min (divided into two
O

30-min testing periods).
 
Stereotyped Sniffing Counts
 
Flupenthixol First 30 Min Second 30 Min
 
0.0 mg/kg 2.75 + 1.37 1.63•'±
 
0.025 mg/kg 2.63 + 1.29 0.88 + 0.52A
 
0.1 mg/kg 1.13 + 0.44 0.25 + 0.25A
 
0.4 mg/kg 1.25 + 0.41 0.63 + 0.63A
 
0.8 mg/kg 0.00 + 0.00 0.00 + O.OOA
 
^Significant time main effect indicating that the total
 
number of sniffing counts in the second 30-min
 
testing period was significantly different from the
 
the first 30-min testing period, P<0.05.
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Discussion
 
The goal of this experiment was to determine the
 
effects of flupenthixol, a DA antagonist, on U,50-488­
induced behaviors. Flupenthixol did produce a decline
 
in U-50,488-induced behaviors in the 17-day-old rat.
 
This decrease in activity suggests that U-50,488's
 
behavioral effects may work via a dopaminergic
 
mechanism. However, it is possible that flupenthixol
 
may have decreased U-50,488-induced activity by a
 
general depression of motoric functioning. Therefore,
 
subsequdnt experiments were done to further examine the
 
interaction between the kappa opioid and DA systems. To
 
that end, rats were pretreated with the kappa receptor
 
agonist U-50,488, then received either the indirect DA
 
agonist amphetamine or the direct DA agonist NPA. If
 
these drugs are working through a dopaminergic mechanism
 
one would predict that U-50,488 pretreatment would
 
potentiate DA agonist-induced activity.
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 Experiraent 3a
 
The Effects of Afflphetamine of NEA on U-50 i 438^Induced
 
Behaviors in the 17-Day-Old Rat
 
The &oal of the present experiment was to determine
 
whether the kappa opioid and T)A agonists activatp
 
behavior through the same mechanism. More^ specifically,
 
if U-50,488 potentiated amphetamine's and/or NPA's
 
locomotor activating effects it would suggest that these
 
drugs are ultimately activating the same pathways.
 
Method ; ■ 
Sub.iects. Forty-eight male a,nd female 17-day-old
 
Sprague-Dawley albino tats (Harlan) were used.
 
Procedures. Six groups of 17-day-old rats (n = 8)
 
received an acute injection of U-50,488 immediateTy
 
pr-ior to a 60-min behavioral testing session. Subjects
 
then received an acute injection of amphetamine, NPA, of
 
saline 30 min into the behavioral testing session. One
 
hour after behavioral testing, rats were anesthetized
 
with phenobarbital and rapidly perfused with 4%
 
paraformuldehyde fpr later analysis of Eos
 
\immunbroaetivity.'';tt''
 
■ Result's-"'^ 
Line-crosses. Overall. 17-day-old rats treated 
with U-50,488 had significantly more line-crosses than 
saline-1reated rats acroSs the initia1 three testing 
blocks (see left panel, Figure 7) [Pre X Time 
55 
interactibhj F(2;,92)=24;35, i^O.001; and Tukey tes P<
 
0.051. Interestingly, across the final three testing
 
blocks, NPA produced a progressive deeline in U-50,488­
induced 1ine-crosses; v)hereas, amphetamine had no effect
 
on U-50,488-induOed activity (see upper graph, right
 
panel, Figure 7) [Pre X Post X Time interaction,
 
F(4,8,4)=7.95, ;p<0.0 tests, P<0.05]. ^
 
By itself, NPA sigrxificantly increased the 1ine­
crosses of saline-pretreated rats (lower graph, right
 
panel, Figure 7); howeyer, rats given both U-50,488 an
 
NPA did not differ from rats given NPA a1one [Pre X Post
 
X Time interaction, F(4,84)=7.95, PCO,001; and Tukey
 
testsj P<0.05]. Amphetamine alone also significahtly c
 
;increa:sed the line-crosses Of saline-pretreated rats
 
(lowOr graph, right panel, Figure 7) [Tukey tests,
 
P<Q.05]. Rats given both U-sp,488 and amphetamine had
 
significantly more 1ine-crOsSeS than rats given
 
amphetamine alone [Tukey tests, P<0.05] (right POhO1,
 
;-'Figure-'7
 
Stereotyped sriiffing. The were no significant
 
differences between saline- Or U-50,488-pretreated rats
 
during the initial 30-mih testing period. Overali; U-

50,488-treated rats had significantly fewer stereotyped
 
Sniffing counts than saline-pretreated rats during the
 
final testing period (see Table 6) [pre main effect,
 
=4.42, P<0.05]. This effect was entifely due to
 
56
 
NPA's actions however, as rats given NPA had
 
significantly more stereotyped sniffing counts than the
 
saline controls during the second SO-min testing period
 
[post main effect, F{2,47)=65.17, P<0.001; and Tukey
 
tests, P<0.0 5 ].
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FIGURE CAPTION
 
Figure 7. Mean number of line-crosses during the 60-min
 
behavioral testing session. The i7-day-old rats (n = 8)
 
were injected v/ith U-50,488 (5.0 mg/kg, s.c.) or saline
 
immediately prior to behavioral testing. Rats were then
 
injected w11h amphetamine ( .5 mg/kg ^ i.p.)^ NPA (1.0
 
mg/kg, i.p.) or saline 30 min into the testing session.
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Table 6. Mean stereotyped sniffing counts (+SEM) of 17­
day-old rats given U-50,488 (5.0 mg/kg) or saline
 
immediately prior to behavioral testing. NPA (1.0
 
ri g/kg), amphetamine (2.5 mg/kg) or saline were then
 
administered 30 min into the testing session, with
 
sniffing being assessed for an additional 30 min.
 
Stereotyped Sniffing Counts
 
Drug Treatment First 30 Min Second 30 Min
 
U-50,488/NPA 2.00 + 0.82 30.72 + 5.88AB
 
Saline/NPA 0.75 + 0.49 42.62 + 5.28®
 
U-50,488/Sa1ine 1.75 + 0.52 1.25 + 0.86A
 
Saline/Saline 1.12 + 0.66 0.62 + 0.49
 
U-50,488/Amphetamine 1.12 + 0.39 2.00 + 1.10A
 
Saline/Amphetamine 1.50 + 0.53 8.37 + 2.34
 
^Significant pre main effect indicating that the U-

50,488-pretreated rats were significantly different
 
from the saline-pretreated rats, P<0.05.
 
^Significant post main effect indicating that the NPA-

treated rats were sigificantly different from the
 
amphetamine- and saline-treated rats, P<0.05.
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Discussion
 
Results showed that amphetamine had only trivial
 
effects on U50-488's stereotyped sniffing and locomotor
 
activating effects. Unexpectedly, NPA dramatically
 
reduced U-50,488-induced locomotor activity. When given
 
alone, NPA increased the stereotyped sniffing of both U­
50,488- and saline-pretreated rats.
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 ; /;:;ExpeTim;erit\ ; ■ 
The Effects of Amphetataine or NPA ott U-50,488-Induced
 
Behaviors in' the 8O-0ay-^dld Rat
 
Method >,
 
Subiects. Forty-eight male and female 80-day-old
 
Sprague^Dawley aibino rats (Har1an) were used.
 
Procedures. Six groups of 80-day*-old rats (n = 8)
 
received ail aeute injectioh(of U-5Q,48 immediately
 
prior to a 1 hr behavioral testing sessiont Subjects .
 
then receiyed an acute injection of amphetamine, NPA, or
 
saline 30 min into the behaviorai testing session. One
 
hour after behavioral testing, rgts were anesthetized
 
with phenobarbital and rapidly perfused with 4%
 
paraformaldehyde testing for later analysis of Fos
 
immunoreactivity.
 
Results ■'
 
Line-crosses. During the initial three testing
 
blocks there were no significant differences between 80­
day-old rats treated with either U-50,488 or saline (see
 
left panel. Figure 8), During the final three testing
 
blocks amphetamine-treated rats had significantly more
 
1ine-crosses than rats receiving saline (see right
 
panel. Figure 8) [post main effect, F(2,42)=9.40,
 
P<0.001; and Tukey tests, P<0.05]. During the fourth
 
testing block rats given U-50,488 alone had
 
significantly fewer line-crosses than al1 other rats
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(see right panel. Figure 8) [Pre X Post X Time
 
interaction, F(4,84)-3.16, P<0.05• and Tukey tests,
 
P<0.05]. During the final two testing blocks, rats
 
receiving amphetamine alone had significantly more line-

crosses than the saline groups [Tukey tests, P<0.05].
 
Stereotyped sniffing. During the initial testing
 
period there were no significant differences in sniffing
 
between the U-50,488- and saline-treated rats (see Table
 
7). During the final testing period, rats pretreated
 
with U-50,488 had significantly fewer stereotyped
 
sniffing counts than saline-pretreated rats [pre main
 
effect, P(1,47)=5,68, P<0.05]. This effect was entirely
 
due to NPA's actions, as rats given NPA had
 
significantly more stereotyped sniffing counts than
 
their saline controls during the final testing period
 
[post main effect, P(2,47)=157.81, P<0.001; and Tukey
 
tests, P<0.05].
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FIGURE CAPtlbN;­
Figure 8. Mean number of line-cfosses during the 60-m^^^^f^
 
behavioral testing sessidn. The rats (n = 8)
 
were injected with U-50,488 (5,0 mg/kg, s.c.) or saline
 
immediately prior to behavioral testing. Rats were then
 
injected with amphetamine (2.5 mg/kg, i.p.), NPA (1.0
 
i.p.) or saline 30 min intp the testing session.
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Table 7. Mean stereotyped sniffing counts (+SEM) of 80­
day-old rats given U-50,488 (5.0 mg/kg) or saline
 
immediately prior to behavioral testing. NPA (1.0
 
mg/kg), amphetamine (2.5 mg/kg) or saline were then
 
administered 30 min into the testing session, with
 
sniffing being assessed for an additional 30 min.
 
Stereotyped Sniffing Counts
 
Drug Treatment First 30 Min Second 30 Min
 
U-50,488/NPA 4.62 + 2.56 50.00 6.79AB
 
Saline/NPA 5.38 + 1.39 66.13 + 2.83B
 
U-50,488/Saline 3.88 + 0.90 3.38 + 1.84A
 
Saline/Saline 6.38 + 2.04 5.38 + 2.31
 
U-50,488/Amphetamine 6.87 + 2.21 4.00 + 0.92A
 
Saline/Amphetamine 7.63 + 2.23 6.12 + 2.91
 
^Significant pre main effect indicating that the U­
50,488 groups were significantly different from the
 
saline-pretreated groups, P<0.05.
 
^Significant post main effect indicating that the NPA-

treated groups were significantly different from all
 
other groups, P<0.05.
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Discussion
 
As predicted, U-50,488 did not enhance the
 
behavipralo of the 80-day-old rat.
 
Amphetaniine did enhance the locomotor activity of the
 
adult rats, while having no effect on stereotyped
 
sniffing. Conversely, NPA increased the sniffing of 80­
day-old rats, while having no effect on locomotor
 
activi.ty. ,
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-.Experiment,3c
 
The Effects of U-50,488, Amphetamine, and NPA,
 
on Eos Immunoreactivity in the Preweanling and Adu11 Rat
 
Method
 
Sub.iects. Ninety-six male and female 17- and 80­
day-bid Sprague-Dawley rats (Harlan) were used. These
 
rats were subjects from iExperiments 3a and 3b.
 
Supplies. The primary antibody was a monQclonai
 
antibody made to the N-terminal end of the Eos molecule
 
in mouse myeloma cells (generously supplied from the
 
laboratpries of Era,nk Sharp and Stephen sagaf); This
 
primary antibody recoghizes EbS and not Eos-related
 
antigens. The secondary antibody was a biotinylated
 
mouse-anti-rat secondary antibody (Vector Laboratories,
 
Inc., Burlingame, CA, USA). An avidin-biotin­
horseradish peroxidase conjugate from an ABC horse kit
 
was also used (Vector Laboratories, Inc.).
 
Procedures. Eollowing a postfixation period, 100
 
micron sections were cut from each brain using a
 
Vibratome 1000 (Ted Pella, Inc., Redding, CA, USA). The
 
sections were washed three times with 0.1 M phosphate
 
buffer (PB) before being incubated with the Eos primary
 
antibody at a 1:50,000 dilution in HSS (0.1 M PB
 
containing 2% horse serum, 0.1% triton-XlOO, and 0.1%
 
bovine serum albumin). Sections were incubated in the
 
primary antibody for 48-72 hr. Control sections from
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each rat were run in the absence of the primary
 
antibody. All sections were then washed three times in
 
PB and incubated with a biotinylated mouse-anti-rat
 
secondary antibody for 2 hr (1:1Q,66d di1ution in HSS),
 
Sections were washed th imes in PB and incubated for
 
2 hr in avldiri-biotin-^horseradish peroxidase cohjugate
 
from ABC horse kitsr Sections were then washed three
 
more times and the Fos protein was visualized using
 
3,3'-diaminobenzidine tetra,hydrochlor^^ hydrogen
 
peroxide. Sections were then rinsed in PB and mounted
 
on chrom-alum slides. The slides were then air dried,
 
dehydrated, and covers1ipped with permount. Al1 washes
 
lasted 5 min. This general procedure was based on the
 
method of Sharp et al. (1989).
 
A total of 6 rats from each drug treatment group
 
were randomly chosen for analysis of Fos
 
immunoreactivity. Similar coronal sections from each
 
rat were selected for quantitative analysis. The number
 
of distinguishable immunoreactive nuclei present within
 
the core and shell of the nucleus accumbens (1.7 A), the
 
dorsal and ventral striatum (1.7 A), amygdala (3.8 P),
 
septal area (0.3 P), olfactory tubercules (1.7 A),
 
anterior cingulate cortex (1.7 A), stria medullaris (3.8
 
P), habenula (3.8 P), posterior hypothalamus (3.8 P),
 
preoptic area (1.7 A), rhomboid nucleus (3.8 P), zona
 
incerta (3.8 P), and piriform cortex (1.7 A) iyere
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manually counted using a magnifieatidh . (The
 
numbers in parentheses represent sections either
 
anteriQi or jpbsterior to bregma, accbrdiilg to the rat
 
brain atlas of Pellegrino & Cushmahi 19l67>) At each
 
region, specific sam^^ areas were counted with the size
 
of the saraple area^ b^^ X 10 mm.
 
Results
 
Effects of U-50.488. amphetamine, and NPA on Fos
 
immunoreaetivity in i7-day-old rats. U-50,488 enhanced
 
Fos immunoreacfiyity in specific brain regions of the
 
preweanling rat (see Figures 9-21). That is, compared
 
to rats given saline, U-50,488 signifleantly enhanced
 
the number of Fos-positive nuclei in the striatum,
 
olfactory tubercles, piriform cortex, habenula, preoptic
 
area, amygdala, stria medullaris, cingulate cortex, and
 
septal area [1(10)=3.73, P<0.01; t(10)=3.21, P<0.01;
 
t(10)=2.24, P<0.05; t(10)=3.09, P<0.05; t(10)=3.72,
 
P<0.01; t(10)=2.99, P<0.05; t(10)=4.28, P<0.01; t(10)=
 
3.52, P<0.01; t(10)=3.44, P<0.01, respectively].
 
Moreover, collapsed across the posttreatment, 17-day-old
 
rats given U-50,488 had significantly more Fos-positive
 
niiclei than saline-treated rats in the striatum,
 
piriform cortex, habenula, preoptic area, amygdala, and
 
septal area [pre main effects, P(1,35)=17.29, P<0.001;
 
=7.33, P<0.05; F(1,35)=34.65, P<0.001;
 
=26.77, P<0.001; P(1,35)=5.74, P<0.05;
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F(1,35)=23,42, P<0.001, respectively].
 
Amphetamine and NPA also had their own effects on
 
Fos immunoreactivity. For example, amphetamine
 
significantly attenuated U-50,488-induced Fos expression
 
in the olfactory tubercles (see Figure 10) [Pre X Post
 
interaction, F(2,35)=5.38, P<0.01; and Tukey tests,
 
P<0.05]. Similarly, NPA significantly depressed U-

50,488-ihduced Fos expression in the striatum [Tukey
 
tests, P<0.05]. Conversely, amphetamine and NPA
 
enhanced the number of Fos-positive nuclei in the
 
piriform cortex (see Figure 13) [post main effect,
 
P(1,35)-3.17, P<0.65]. In the cingulate cortex, 17-day­
old rats given ampheta.mine alone had significantly more
 
Fos-positive nuclei than rats in the saline control
 
group [Pre X Post interaction, P(2,35)=3.58, P<0.05; and
 
Tukey tests, p<0.05].
 
Effects of amphetamine. NPA. and U-50.488 on Fos
 
immunoreactivity in 80-day^old rats. In general, U­
50,488 did not affect Fos expression in 80-'day-old rats.
 
The one exception was the ha.benula, where there were
 
more Fos-ppsitive nuclei in the U-50,488-pretreated
 
rats than in the saline-pretreated rats (see Figure 22)
 
[pre main effect, P(1,35)=6.62, P<0.05].
 
NPA signifrcahtly;increased Fos expression in the
 
piriform cortejt, an effect attenuated by U-50,488
 
bretreatment (see Figure 23) tPre X Post interaction.
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F(2,35)=6.37, P<0.01; arid Tukey tests, P<0.05}. NPA
 
also reduced the mean number of Fos-positive nuclei in
 
the olfactory tubercles, however this was apparent in
 
both the saline- and U-50,488-pretreated rats (See
 
Figure 24) [post main effect, P(2,35)=4.34, P<0.05; and
 
Tukey tests, P<0.05].
 
Amphetamine only affected Fos expression
 
in the zona incerta, In this particular region,
 
amphetamine decreased the number of Fos-positive nuclei
 
relative to the saline-treated rats (see Figure 25)
 
[post main effect, P(2,35)=3.87, P<0.05; and Tukey
 
tests, P<0.05].
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FIGURE CAPTION
 
Figure 9. Mean number (+SEM) of Fos-positive nuclei
 
throughout the striatum of the 17-day-old rat (n = 6).
 
The rats were sacrificed 60 min after behavioral testing
 
and were the same rats as those described in Figure 7.
 
^Significant t-test indicating that the U-50,488/saline
 
group was significantly different from the saline/saline
 
group, P<0.01. ^significant pretreatment main effect
 
indicating that U-50,488-pretreated rats were
 
significantly different from saline-pretreated rats,
 
P<0.001.
 
73
 
 1 7—Day—Olds 
60 60 
A 
I I Saline a 
^AMPH 
40­ -40 
15 
+-» 
O 
20­ -20 s> (/) 
0 ririf"iMh 0 
Control Saline U50488 
FIGURE CAPTION
 
Figure 10. Mean number (+SEM) of Fos-positive nuclei
 
throughout the olfactory tubercles of the 17-day-old rat
 
(n = 6). The rats were sacrificed 60 min after
 
behavioral testing and were the same rats as those
 
described in Figure 7. ^Significant Pre X Post
 
interaction indicating that the U-50,488/saline and U­
50,488/NPA groups were significantly different from
 
their respective saline-pretreated control groups,
 
P<0.05. ''Significant Pre X Post interaction indicating
 
that the U-50,488/amphetamine group was significantly
 
different from the U-50,488/saline group, P<0.05.
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Figure 11. Mean number (+SEM) of Fos-positive nuclei
 
throughout the piriform cortex of the 17-day-old rat {n
 
= 6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 7. ^Significant t-test indicating that the U­
50,488/saline group was significantly different from the
 
saline/saline group, P<0.05. ^Significant pre main
 
effect indicating that U-50,488-pretreated rats were
 
significantly different from saline-pretreated rats,
 
P<0.05. ^Significant post main effect indicating that
 
the amphetamine- and NPA-treated rats were significantly
 
different from their saline-treated controls, P<0.05.
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Figure 12. Mean number (+SEM) of F'os-pdsitive nuclei
 
throughout the habenu1a of the 17-day-oId rat (h - 6).
 
The rats were sacrificed 60 min after behavioral testing
 
and were the same rats as thoSe described in Figure 7.
 
^Sighificant t-test inclicatihg that thd 0^50v488/sali
 
group was significantly different from the saline/salihe
 
group, P<0.05. ASignificant pre main effeet indicating
 
that U-50,488^pretreated rats were significantly
 
different from the saline-pretreated rats, P<0,0U1•
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Figure 13. Mean number (+SEM) of Fos-positive nuclei
 
throughout the preoptic area of the 17-day-old rat (n =
 
6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 7. ®^Significant t-test indicating that the U­
50,488/saline group was significantly different from the
 
saline/saline group, P<0.01. ^Significant pre main
 
effect indicating that U-50,488-pretreated rats were
 
significantly different from saline-pretreated rats,
 
P<0,001.
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Figure 14. Mean number (+SEM) of Fos-positive nuclei
 
throughout the amygdala of the 17-day-old rat (// = 6).
 
The rats wefe^^ 60 min after behavioral testing
 
and were the same rats as those described in Figure 7. ;
 
^Significant t-test indicating that the U-50,488/saline
 
group was significdntly different from the saline/saline
 
group, F<0.05. ^Significant pre main effect indicating
 
that U-50,488-pretreated rats were significantly
 
different from saline-pretreated rats, P<0.05.
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Figure 15. Mean number (+SEM) of Fos-posi1 nuclei
 
throughbut the stria medullaris of the 17-day-old rat (n
 
= 6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 7.^ ®Significant t-test indidating that the U­
50j488/saiine group was significahtly different from the
 
saline/saline group, P<0.01.
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Figure 16. Mean number (+SEM) of Fos-positive nuclei
 
throughout the cingulate cortex of the 17-day-ol<i rat (n
 
= 6). The rats were sacrificed 60 miri after behavioral
 
testing and were the same rats as those described in
 
Figure 7. ^Significant t-test indicating that the
 
50^ 488/saline group was Significahtly different from the
 
saline/saline group, F<0-05. ^'Significant Pre X Post
 
interaction indicating that the saline/amphetamine group
 
was significantly different from the saline/saline
 
group, P<0.05.
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Figure 17. Mean number (+SEM) of Fos-positive nuclei
 
throughout the septal area of the 17-day-old rat (n =
 
6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 7. ^Significant t-test indicating that the U­
50,488/saline group was significantly different from the
 
saline/saline group, F<0.01. ^Significant pre main
 
effect indicating that U-50,488-pretreated rats were
 
significantly different from saline-pretreated rats,
 
P<0.001.
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Figure 18. Mean number (+SEM) of Fos-positive nuclei
 
throughout the nucleus accumbens of the 17-day-old rat
 
(n = 6). The rats were sacrificed 60 min after
 
behavioral testing and were the same rats as those
 
described in Figure 7.
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Figure 19. Mean niimber (+SEM) of Fos-positive nuclei
 
throughout the posterior hypothalamus of the 17-day-old
 
rat (n = 6). The rats were sacrificed 60 min after
 
behavioral testing and were the same rats as those
 
described in Figure 7.
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Figure 20. Mean number (+SEM) of Fos-positive nuclei
 
throughout the rhomboid nucleus of the 17-day-old rat (n
 
= 6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 7.
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Figure 21. Mean number (+SEM) of Fos-positive nuclei
 
throughout the zona incerta of the 17-day-old rat (n =
 
6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 7.
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Figure 22. Mean number (+SEM) of Eos-positive nuclei
 
throughout the habenu1a of the 80-day-oId rat (^ = 6).
 
The rats were sacrificed 60 min after behavioral testing
 
and were the same rats as those described in Figure 8.
 
''^Significant pre main effect indicating that U-50,488^
 
pretreated rats were sighifieantly different from
 
salinb--pretreated fats, f^OiObi.
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Figure 23. Mean number (+SEM) of Fos-positive nuclei
 
throughout the piriform cortex of the SO-day-old rat (n
 
=6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 8. ^Significant Pre X Post interaction
 
indicating that the U-50,488/NPA group was significantly
 
different from the saline/NPA group, P<0.05.
 
''Significant Pre X Post interaction indicating that the
 
saline/NPA group was significantly different from the
 
saline/saline group, P<0.05.
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Figure 24. Mean number (+SEM) of Fos-positive nuclei
 
throughout the olfactory tubercles of the 80-day-old rat
 
{n = 6). The rats were sacrificed 60 rain after
 
behavioral testing and were the same rats as those
 
described in Figure 8. ^Significant post main effect
 
indicating that the NPA-treated rats were significantly
 
different from their saline-treated controls, P<0.05.
 
103
 
  
80—Day—Olds 
CO 50-1 
CD I Saline 
O 
40­ AMPH -40 
0 NPA 
JZ) 
15 30­ -30 
1— 
b 20­ 20 o 
0
1 J 
1 * 
o 10­ -10 
o 
M— B 
O 0­ 0 
Control Saline U50488 
 ■ fig)[jre;::gaption^:-'- ;^ ■ 
Figure 25. Mean number (+SEM) of Fos-positive nuclei
 
throughout the zona ihcerta of the 80-day-old rat (n =
 
6). The rats were sacrificed 60 min after behavioral
 
testing and werd^^^ as thpse described in
 
Figure 8. ®Significant post main effect inidieating that
 
the NPAvtfeated rats were significantly diffefent f
 
their saline-treated controls, P<0.05;
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Figure 26. Mean number (+SEM) of Fos-positive nuclei
 
fhroughout the striatum of the 80-day-old rat {n = 6)•
 
The rats were sacrificed 60 min after behavioral testing
 
and were the same rats as those described in Figure 8.
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Figure 27. Mean number (+SEM) of Fos-positive nuclei
 
throughout the preoptic area of the 80-day-old rat (n
 
6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 8.
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Figure 28. Mean number (+SEM) of Fos-positive nuclei
 
throughout the amygdala of the 80-day-old rat (n = 6).
 
The rats were sacrificed 60 min after behavioral testing
 
and were the same rats as those described in Figure 8,
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Figure 29. Mean number (+SEM) of Fos-positive nuclei
 
throughout the septal area of the 80-day-old rat (n =
 
6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 8.
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Figure 30. Mean number (+SEM) of Fos-positive nuclei
 
throughout the cingulate cortex of the 80-day-old rat {n
 
= 6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
Figure 8.
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Figure 3i. Mean number (+SEM) of Fos-positive nuclei
 
throughout the stria medullaris of the 80-day-old rat (n
 
- 6). The rats were sacrific 60 min after behavioral
 
testing a.nd were the same rats as thbse described in
 
Figure 8.
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Figure 32. Mean number (+SEM) of Fos-positive nuclei
 
throughout the nucleus accumbens of the 80-day-old rat
 
(n = 6). The rats were sacrificed 60 min after
 
behavioral testing and were the same rats as those
 
described in Figure 8.
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Figure 33. Mean number (+SEM) of Fos-positive nuclei
 
throughout the posterior hypothalamus of the 80-day-old
 
rat (n - 6)• The rats were sacrificed 60 min after
 
behavioral testing and were the same rats as those
 
described in Figure 8.
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Figure 34. Mean number (+SEM) of Fbs-positlveriuelei
 
thrpugliout tbe rhomboid nucleus Of the 80-day-old rat (n
 
- 6). The rats were sacrificed 60 min after behavioral
 
testing and were the same rats as those described in
 
■Eigure. .8.. . 
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Piscussion
 
The 17-day-old rats treated with U-5d,488 displayed
 
an increased number of Fps-positive nuclei in several
 
brain regions, suggesting Ipcatidns where the DA and
 
kappa opioid systems may ihteract. Interestingly, U­
50,488 dramatically enhanced Fos expression in the
 
striatum of the 17-day-old rat/ This is partidularly
 
important because the striatum is known to be involved
 
in the mediation of Ibcomotor activity, rearing, and
 
grooming (Arnt, 1987; Bofdi et al., 1989). In the
 
present study, NPA dramatically reduced U-50,488-induced
 
Fos expressioh in the striatum. This pattern of
 
neuronal activity correlates with behavior, as NPA
 
depressed U-50,488-induced locomotor activity in the
 
preweanling rat (see Experiment 3a). Similarly,
 
amphetamine decreased U-50,488-induced Fos expression in
 
the olfactory tubercles of the 17-day-old rat. The
 
olfactory tubercles are involved in learning and memory
 
and have been associated with conditioned place
 
aversions (Ehret & Buckenmaier, 1994). Although
 
speculative, it is possible that these Fos effects may
 
be due to amphetamine attenuating U-50,488's aversive
 
properties.
 
Several other brain regions of the 17-day-old rat
 
displayed increased Fos immunoreactivity in response
 
to U-50,488. Fos expression was enhanced by U-50,488 in
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the cingulate cortex, septal area, and preoptic area. 
These brain regions mediate a variety of behaviors. For 
example, the septal area mediates analgesia, aversions, 
aggression, and locomotor activity (Noltej 1981; Roeling 
et al., 1994; Schwarting & Huston, 1992). The cingulate 
cortex arid preoptic area are involved the mediation of 
emotion, memory, reproductive behaviors, and motoric 
functioriing (Agmo & Villalpando, 1995; Kopb & Swerdlow, 
1988; Vogt, Finch, & Olson, 1992). However, common to 
each of these brain regions is participation in the 
modulation of lOcomotor activity. U^50,488's neuronal 
activation in these areas is consistent with the 
increased locomotor activity displayed after 11-50,488 
treatment in the 17-day-old rat (see Experiments la and 
3a). ■ ■ 
U-50,488 also enhanced Fos expression in the
 
piriform cortex, habenula, amygdala, and septal area of
 
the 17-day-o1d rat. These brain regions are irivo1ved in
 
the mediation of a number of behaviors. For example,
 
the piriform cortex and habenula mediate olfactiori,
 
conditioned taste aversions, ari^lsesia, and sexual
 
activity (Hasselmo, 1995; Lee & Huang, 1988; Werka,
 
Skar, & Ursin, 1978). The amygdala and septal area are
 
involved in conditioned place aversions, maternal
 
behavior, analgesia, and aggression (Schwarting &
 
Huston, 1992; Umino, Nishikawa, & Takahashi, 1995).
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Overall, these brain areas share the common feature of
 
being involved in the mediation of analgesia and
 
aversions. It is known that kappa opioid agonists
 
produce analgesia and aversions in the preweanling rat
 
(Barr, 1992; Barr et al., 1986, 1994); therefore, it is
 
not surprising that U-50,488 produced Fos expression in
 
these brain regions.
 
Amphetamine and NPA also affected Fos
 
immunoreactivity in the preweanling rat. Both of the DA
 
agonists increased Fos expression in the piriform
 
cortex, an area involved in the mediation of sniffing
 
and exploratory behavior (Hasselmo, 1995; Nolte, 1981).
 
Thus, amphetamine and NPA increase sniffing and
 
locomotor activity in 17-day-old rats, while
 
increasing Fos expression irl the piriform cortex.
 
Amphetamine also increased Fos induction in the
 
cingulate cortex of the preweanling rat. Dopamine
 
receptor activation in the cingulate cortex enhances
 
locomotor activity (Agmo & Villalpando, 1995; Devinsky,
 
Morrell, & Vogt, 1995).
 
With one exception, U-50,488 did not increase Fos
 
immunoreactivity in 80-day-old rats. In the habenula,
 
Fos expression was enhanced after U-50,488 treatment.
 
Neuronal activation in the habenula is involved in
 
olfaction, analgesia, sexual behaviors, and aversions.
 
U-50,488 is known to produce both conditioned place and
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x
 
taste aversions in the rat (Bart, 1992; Bechara & Van
 
der Kooy, 1987; Lee & Huang, 1988; Thorntpn & Davies,
 
1991). Therefore, it is possible that U-5d,488's
 
aversive properties may be inediated in this area.
 
Alternatively, U-SO,488 attenuated NPA-induced sniffing,
 
so it is possible that Fos expression In the habenula
 
reflects sniffing or olfactory effects, rather than
 
aversions.
 
Consistent with the antagonistic relationship
 
displayed in the preweanling rat, U-50,488 also
 
attenuated NPA-induced Fos expression in the piriform
 
cortex of the adult rat. The piriform cortex is an
 
olfactory relay center and this neuronal interaction
 
between U-50,488 and NPA coincides with U-50,488's
 
ability to depress NPA-induced sniffing (see Tables 3
 
and 6).
 
Treatment with DA Agonists alone also affected Fos
 
immunoreactivity in the 80-day-old rat. For example,
 
amphetamine decreased Fos expression in the zona incerta
 
of the adult rat, an area involved in the modulation of
 
ingestive behaviors (Ricardo, 1981; Tonelli &
 
Chairaviglio, 1995). NPA reduced Fos expression in the
 
olfactory tubercles of the 80-day-old rat. The
 
olfactory tubercles are involved in mediating shiffing
 
and exploratory behavior (Hasselmo, 1995), The fact
 
that amphetamine and NPA affected Fos expression in
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these brain areas is not surprising as these regions are
 
densely populated with dopamine receptors (DeutGh, Taniv
 
& Roth, 1985; Leibowitz & Rossokis, 1979; Stein/ Carr, &
 
Simon, 1990.).v'
 
In summary, a numbdr of brain regions showed drug-

induced Fos expression. Aithough we attempted to make
 
comparisons between regional Fos expression and
 
behavior, it is important to realize that such
 
comparisons must be interpreted with a great deal of
 
caution. The brain regions showing Fps activity mediate
 
a variety of behaviors and, in many cases, it is very
 
speculative to 1ink drug-induced behavioral effects with
 
Fos. Even so, U-50,488 did dramatically enhance Fos
 
expression in the striatum of the 17-day-old rat, an
 
effect blocked by NPA treatment. This pattern of Fos
 
activity is consistent with NPA's effects on U-50,488­
induced locomotor activity (see Experiment 3a) When
 
considered together, these results suggest that the
 
striatum may be involved in the mediation of U-50,488's
 
locombtor activating effects.
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Experi-ment; 4
 
The Behavioral Effects of NPA on U--50,48S-In^^^^
 
Behaviors in 17-Day-Qld Rats
 
It was predicted that NPA and amphetainine would
 
potentiate u-50,488-induced locomotor actiylty in the
 
preweaniing rat. In Experiment 3, however, a single
 
dose of NPA was found to attenuate U-5d,488-induced
 
behaviors in the 17-day-old rat, while amphetamine left
 
these behaviors unaffected. A possible explanation for
 
these data ia that combined treatment with U-50,488 and
 
NPA produced intense stereotypical behaviors not
 
measured in the last experiment. To assess this
 
possibility, U-50,488-pretreated rats received lesser
 
doses of NPA that should produce locomotor activity
 
without inducing stereotypical behaviors.
 
Methods
 
Subiects. Eighty male and female 17-day-old
 
Sprague-Dawley albino rats (HarIan) were used.
 
Procedures. Ten groups of 17-day-old rats (n = 8)
 
received an acute injection of U-50,488 (5.0 mg/Rg,
 
s.c.) immediately prior to a 60-min behavioral testing
 
:session. Rats then received an aCute injeCtion of NPA
 
(0.0, 0.001, 0.01, 0.1, or 1.0 mg/kg, i.p.) 30 min into
 
the testing session.
 
Results
 
Line-crosses. During the initial three testing
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blocks rats given U-50,488 had significantiy more line-

crosses than saline-treated rats (left jjanel. Figure 35)
 
[pre main effect, F(l,78)=470.08, P<0.001]. During the
 
final three testing blocks, NPA attenuated U-50,488­
induced line-crosses in a dose-dependent manner (upper
 
graphs right panel. Figure 35) [Pre X Post interaction,
 
F(4,70)=12;02j P<0.001; and Tukey tests, P<0.05). For
 
instance, the 1.0 mg/kg dose of NPA produced the
 
greatest decline in U-50,488-induced locomotor activity,
 
with 0.1 and 0.01 mg/kg NPA producing a moderate decline
 
in activity (see upper graph, right panel. Figure 35)
 
[Tukey tests, P<0.05].
 
In contrast, when given alone, NPA enhanced the
 
locomotor activity of the 17-day-old rats (see lower
 
graph, right panel. Figure 35) [Pre X Post interaction,
 
P(4,70)=12.02, P<0.001; and Tukey tests, P<0.05]. The
 
0.01 mg/kg NPA produced the' most line-crosses, with 0.1
 
and 1.0 mg/kg NPA producing a moderate amount of
 
activity (Tukey tests, P<0.05).
 
Stereotvped sniffing. During the first testing
 
period, sniffing was not affected by U-50,488
 
pretreatment [U-50,488: 2.00 + 0•36; saline: 1.07 +
 
0.23]. Oyerall, U-50,488-pretreated rats had
 
significantly fewer sniffing counts than saline-

pretreated rats (see Table 8) [pre main effect,
 
F(1,79)=82.24, P<0.001]. Saiine-pretreated rats given
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0.01, 0.1, or 1.0 mg/kg NPA had significantly more
 
sniffing counts than rats receiving saline [Pre X Post
 
interaction, FC4,79)=13.82, P<0.001; and Tukey tests,
 
P<0.05]. U-50,488-pretreated rats given 0.01, 0.1, and
 
1.0 mg/kg NPA had significantly fewer sniffing counts
 
than similarly treated saline-pretreated rats [Tukey
 
tests, P<0.05].
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FIGURE CAPTION
 
Figure 35. Mean number of line-crosses during the 60­
min behavioral testing session. The 17-day-old rats (n
 
= 8) were injected with U-50,488 (5.0 mg/kg, s.c.) or
 
saline immediately prior to behavioral testing. Rats
 
then received NPA (0.001, 0.01, 0.1, or 1.0 mg/kg, i.p.)
 
or saline 30 min into the testing session.
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Table 8. Mean stereotyped sniffing counts (+SEM) of 17­
day-old rats following treatment with NPA (0.0-1.0
 
mg/kg) 30 min after an initial injection of U-50,488
 
(5.0 mg/kg). Behavioral testing occurred immediately
 
after U-50,488 treatment and was recorded for 60-min
 
(divided into two 30-min testing periods)i Data
 
reported are from the second 30-min testing period. All
 
doses are in mg/kg.
 
Drug Treatment Stereotyped Sniffing Counts
 
Saline/Saline 0.00 + 0.00
 
U-50,488/Saline 0.37^^^^ +
 
Saline/0.001 NPA 5.37 + 1.59
 
U-50,488/0.001 NPA ; 2.87 +1.34
 
Saline/0.01 NPA 30.50 ± 6.36®^
 
U-50,488/0.01 NPA 3.12 + 1.25
 
Saline/0.1 NPA 48.75 + 4.80^^
 
U-50,488/0.1 NPA 8.62+5.52
 
Saline/1.0 NPA 61.37 ± 5.67^"
 
U-50,488/1.0 NPA 16.12 + 5.31
 
^Significant Pre X Post interaction indicating that
 
saline-pretreated rats given NPA were significantly
 
different from the saline/saline group, P<0.05.
 
^Significaht Pre X Post interaction indicating that
 
saline-pretreated rats given NPA were significantly
 
different from similarly treated U-50,488-pretreated
 
rats, P<0.05.
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Discussion
 
NPA increased stereotyped sniffing in saline-

pretreated rats in a dose-dependent manner: an effect
 
attenuated by U-50,488-pretreatment. Conversely, NPA
 
produced a dose-dependent decrease in U-50,488-induced
 
loebmotpr activity. Thus, contrary to the original
 
hypotheses, these resu11s suggesf an antagonistic
 
re1ationship betWeen U-50,488 and NPA.
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Experiment 5
 
The Behavioral Effects of Amphetamine
 
on U-50,488-Induced Behaviors in 17-Day-Old Rats
 
Methods
 
Subjects. Eighty male and female 17-day-old
 
Sprague-Dawley albino rats (Harlan) were used.
 
Procedures. Ten groups of i7-day-old rats (n = 8)
 
received an acute injection of U-50,488 (5.0 mg/kg,
 
s.c.) immediately prior to a 60-min behavioral testing
 
session. Rats then received an acute injection of
 
amphetamine (0.0, 1.0, 2.5, 5.0, 10.0 mg/kg, i.p.) 30
 
min into the behavioral testing session.
 
Results
 
Line-crosses. Overall. there was a general decline
 
in the total number of line-crosses across the final
 
three testing blocks (see upper graph. Figure 36) [time
 
main effect, F(2,70)=12.13, P<0.001; and Tukey tests,
 
i'<0.05]. However, the various doses of amphetamine had
 
inconsistent effects on U—50,488-induced locomotor
 
activity. For example, during the fourth testing block,
 
1.0, 2.5, and 10.0 mg/kg amphetamine produced
 
significantly more iine-crosses than saline; whereas,
 
rats given 5.0 mg/kg amphetamine had fewer line-crosses
 
than rats receiving 1.0 or 10.0 mg/kg amphetamine (see
 
upper graph, right panel. Figure 36) [Post X Time
 
interaction, F'(8,70)=6.01, P<0.001; and Tukey tests.
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P<0.05). During the fifth testing bipck, U-50,488­
pretreated rats given 2.5 or 5.0 mg/kg amphetamine had
 
significantly fewer line-crosses than rats receiving
 
saline, 1.0, or 10.0 mg/kg amphetamine [Tukey tests^
 
P<0,05]. However, by the final testing block, only rats
 
given 2.5 mg/kg amphetamine had sighificantly fewer
 
line-crosses than rats receiving saline. During the
 
final testing block there were no significant
 
differences between the various groups of amphetamine-

treated rats.
 
Stereotyped sniffing. Overall. amphetamine
 
enhanced the stereotyped sniffing of the U-50,488­
pretreated rats (see right panel, lower graph. Figure
 
38) [post main effect, F(4,35)=15.30, P<0.001; and Tukey
 
tests, P<0.05]. There was a progressive increase in
 
stereotyped sniffing during the final three testing
 
blocks [time main effect, P(2,70)=24.26, P<0,001; and
 
Tukey tests, P<0.05]. During the fourth testing block
 
there were no significant differences between rats given
 
amphetamine or saline. However, during the fifth and
 
sixth testing block rats given 5.0 and 10.0 mg/kg
 
amphetamine had significantly more sniffing counts than
 
rats given saline (see right panel, lower graph. Figure
 
38) [Post X Time interaction, P(8,70)=11.54, P<0.001;
 
and Tukey tests, P<0.05]. Not pntil the sixth testing
 
block did 2.5 mg/kg amphetamine produce significantly
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more sniffing than the saline group [Tukey tests,
 
P<0.05].
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FIGURE CAPTION
 
Figure 36. Mean number of line-crosses and stereotyped
 
sniffing counts during the 60-min behavioral testing
 
session. The 17-day-old rats {n = 8) were injected with
 
U-50,488 (5.0 mg/kg, s.c.) immediately prior to
 
behavioral testing. Rats were then given amphetamine
 
(1.0, 2.5, 5.0, or 10.0 mg/kg, i.p.) or saline 30 min
 
into the testing session.
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Discussion
 
Amphetamine produced no definitive pattern of
 
action on U-50,488-induced line-crossing. For example,
 
during the fourth and fifth testing blocks
 
1.0 mg/kg amphetamine produced more locomotor activity
 
than 5.0 mg/kg amphetamine. By the final testing block
 
there were no significant differences between
 
amphetafliine-freated rats. Therefore, while NPA appears
 
to antagonize U-50,488-induced behaviors, amphetamine's
 
actions on U-50,488-induced behaviors are more
 
uncertain. To further examine how the DA and kappa
 
systems interact two subsequent experiments were done.
 
Rats were given amphetamine or NPA for five consecutive
 
days. Following a two day wash-out period, chronically
 
treated rats received a challenge injection of U-50,488
 
and were tested for cross-sensitization. If cross-

sensitization were found between the DA agonists and U­
50,488 this would indicate that the behavioral actions
 
of these drugs are mediated through common dopaminergic
 
mechanisms.
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Experiment 6
 
Cross-Sensitization in the Preweanling Rat:
 
The Behavioral Effects of U-5G,488
 
Following Chronic Treatment with NPA
 
The goal of this study was to determine if kappa
 
opioid and DA agonists enhance locomotor activity
 
through the same mechanisms. In Experiment 6, cross-

sensitization was used to further assess this
 
hypothesis. Sensitization, apparent in both preweanling
 
and adult rats, is characterized by a progressive
 
enhancement of the behavior-activating effects of DA or
 
opiate agonists (see McDougall, Duke, Bolanbs, &
 
Crawford, 1994; Robinson & Becker, 1988; Vezina &
 
Stewart, 1989). Several studies indicate that
 
behavioral sensitization to DA and opiate agonists is
 
produced by modifications in the functioning of
 
nigrostriatal DA neurons (see Hoffman & Wise, 1992;
 
Vezina & Stewart, 1989). For example, amphetamine-

sensitized rats show enhanced striatal DA release in
 
response to amphetamine challenge (Kalivas, 1985;
 
Robinson & Becker, 1986). Similarly, rats sensitized to
 
morphine show enhanced release, synthesis, and
 
metabolism of DA in the nucleus accumbens fpllowing an
 
acute injection of morphine (Kalivas, 1985; Kalivas &
 
Duffy, 1987).
 
Interestingly, some drugs will cross-sensitize to
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one another, suggesting that both drugs are acting on
 
the same systems, For examp1e, rats sensitized with GBR
 
12909 (a DA uptake inhibitbr) show cross-sensitization
 
in response to cocaine (Baldo & Kelly, 1991; Tolliver &
 
Carney, 1994). Similarly, amphetamine-sensitized rats
 
display a sensitized response to cocaine challenge
 
(Kalivas & Weber, 1988). Xmpbrtantly, opiate and
 
DA agonists cross-sensitize to one another. For
 
example, successive intra-ventral tegmental area
 
injections of amphetamine result in a sensitized
 
response to systemic morphine, an effect that is
 
reciprocal (Stewart & Vezina, 1987; Vezina & Stewart, :
 
1990). Since amphetamine appears to induce behavioral
 
sensitization by modulating striatal DA functioning,
 
morphirie's ability to cross-sensitize suggests that
 
these drugs are ultimately working through the same
 
system. Therefore, if U-SO,488 cross-sensitizes with
 
the DA agonists, this would provide evidence that these
 
drugs work through the same mechanisms.
 
Methods
 
Subiects. Thirtv-two male and female 17-dav-old
 
Sprague-Dawley albino rats (Harlan) were used.
 
Procedures. Four groups of 11-day-old rats (n = 8)
 
received injections of NFA (O.O or 1.0 mg/kg, 1.p.) for
 
five consecutive days. GloSs-sOnMtizatioh was examined
 
two days 1ater as the preweanling rats (i.e., at 17 days
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of age) received an acute injection of U-50,488 (5.0
 
mg/kg, s.c.) or NPA (1:0 mg/kg, i/p.) C was
 
added to the behaviors being recorded. A circle count
 
was recorded when the rat turned 360°, with the rear
 
paws as the center point of the circle. Each day a 60­
min behavioral teating session took piace immediately
 
after drug treatment. ,
 
Statistics. To analyze the behavioral data,
 
repeated measure ANOVAs yfere perform acrbss the five
 
days of conditioning, with a separate ANOVA performed
 
for the test day. In 'brder to assess whether NPA
 
produced sensitization a series of t-tests
 
{P<0.05) were performed to examine how the saline-^ and
 
NPA-conditioned rats responded to a challenge dose of
 
NPA.. ■ , 
Results
 
Conditionihg; Effects of NPA on locomotor activitv.
 
Rats receiving NPA had significantly more line-crosses
 
than saline controls across conditioning {see Figure 37)
 
[conditioning main effect, F(1,30)=62.48, P<0.001].
 
Furthermore, NpA produced a progressive increase in
 
line-^crosses from the first to last day of Conditioning
 
(upper graph. Figure 37) [Gonditibning X Day
 
interaction, F(4,120)=29.19, P<0.001; and Tukey tests,
 
P<0.05].
 
Testing: Effects of U-50.488 challenge on locomotor
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activity in NPA conditioned rats. On the test day
 
sensitization was apparent, as rats given NPA during
 
both conditioning and testing had significa.ntly more
 
line-crosses than rats given NPA on Only the test day
 
(see triangles, right panel, Figure 37) [t(14)=2.58,
 
P<0.05]. U-50,488 did not cross-sensitize with NPA,
 
since the two groups challenged with U-50,488 responded
 
similarly oh the test day (see boxes, right panel.
 
Figure 37). On the test day, rats given U-50,488 had
 
significantly more 1ine-crosses than rats given NPA (see
 
right panel, Figure 37) [Condition X Test interaction,
 
F(1,31)-7.28, P<0.05; and Tukey tests, P<0.05].
 
Conditioning: Effects of NPA on stereotvped
 
sniffing. Overall, rats receiving NPA had significantly
 
more stereotyped sniffing counts than saline-treated
 
rats (see Figure 38) [conditiohing main effect,
 
P(1,30)=37.47, P<0.001]. NPA produced a progressive
 
increase in sniffing over the last three days of
 
conditioning (upper graph. Figure 38) [Conditioning X
 
Day interaction, P(4,120)=38.17, P<0.001; and Tukey
 
tests, P<0.05].
 
Testing: Effects of U-50.488 challenge on
 
stereotvped sniffing in NPA—conditioned rats. On the
 
test day, NPA-conditioned rats displayed a sensitized
 
response to N^A. Specifically, when challenged with
 
NPA, rats conditioned with NPA had significantly more
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stereotyped sniffing counts than rats conditioned with
 
saline (see triangles, right panel. Figure 38)
 
[t(14)=3.01, P<0.01]. On the test day, regardless of
 
conditioning, U-50,488 challenge failed to produce any
 
stereotyped sniffing. Thus, rats given NPA on the test
 
day had significantly more stereotyped sniffing counts
 
than rats receiving U-50,488 (see right panel. Figure
 
38) [Conditioning X Test interaction, F(1,31)=9.45,
 
P<0.05; and Tukey tests, P<0.05].
 
Conditioning: Effects of NPA on circling. During
 
conditioning, NPA produced a small, but significant,
 
increase in circling when compared to saline-treated
 
rats (upper graph. Figure 39) [conditioning main effect,
 
P(l,16)=11.64, P<0.05].
 
Testing: Effects of U-50.488 challenge on circling
 
in NPA-conditioned rats. On the test day, rats
 
conditioned with NPA failed to display a sensitized
 
circling response after NPA challenge (see triangles,
 
upper right panel. Figure 39) [t(14)=1.08, P>0.05].
 
When given alone, U-50,488 failed to produce circling;
 
however, NPA-conditioned rats challenged with U-50,488
 
had significantly more circling counts than all other
 
groups (see box, upper right panel. Figure 39)
 
[Conditioning X Test interaction, P(1,24)=21.42,
 
P<0.001; and Tukey tests, P<0.05].
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FIGURE CAPTION
 
Figure 37. Mean number of line-crosses of rats given
 
five daily injections of NPA (1.0 mg/kg, i.p.) or Saline
 
starting at 11 days of age (n = 8). At 17 days of age
 
(i.e., after a 2-day interval), rats given successive
 
saline or NPA injections were then given a single
 
challenge injection of U-50,488 (5.0 mg/kg, s.c.) or NPA
 
(1.0 mg/kg, i.p.).
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FIGURE CAPTION
 
Figure 38. Mean number of stereotyped sniffing counts
 
of rats given five daily injections of NPA (1.0 mg/kg,
 
i.p.) or saline starting at 11 days of age (n = 8). At
 
17 days of age (i.e., after a 2-day interval), rats
 
given successive saline or NPA injections were then
 
given a single challenge injection of U-50,488 (5.0
 
mg/kg, s.c.) or NPA (1.0 mg/kg, i.p.).
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Figure 39. Mean number of circling counts of rats given
 
five daily injections of NPA (1.0 mg/kg, i.p.) or saline
 
starting at 11 days of age {n = 8). At 17 days of age
 
(i.e., after a 2-day interval), rats given successive
 
saline or NPA injections were then given a single
 
challenge injection of U-50,488 (5.0 mg/kg, s.c.) or NPA
 
■(:f.O' - mg/kg, /i..p,. 
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Discussion
 
No evidence for cross-sensitization between NPA and
 
U-50,488 was apparent. On the test day, rats
 
conditioned with NPA did display sensitized Ibcomotor
 
activity and stereotyped sniffing. Interestingly, U­
50,488 challenge significantly enhanced circling in NPA-

conditioned rats. These results support the findings of
 
earlier experiments (i.e.. Experiments 3a and 4)
 
suggesting that a generally antagonistic relationship
 
exists between U'-50,488 and NPA.
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Experiment 7
 
Cross-Sensitization Preweanling Rat:
 
The Behavioral Effects of U-SO,488^^^^ '
 
Following Chronic Treatment with Amphetamine 
Methods ■ 
Subiects Thirtv-two male and female 17-day-old
 
Sprague-Dawley albino rats (HarIan) were usedv
 
Procedures. Four groups of 11-day-old rats {n = 8)
 
received injections of amphetamine (0.0 or 2.5 mg/kg,
 
i.p.) for five consecutive days. Crpss-sensitization
 
was examined two days later as the preweanling rats (17
 
days old) received an acute injection of U-50,488 (5.0
 
mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.). Each day
 
a 60-min behavioral testing session began immediately
 
drug treatment.
 
Statistics. To analyze the behavioral data,
 
repeated measure ANOVAs were performed across the five
 
days of conditioning, with a separate ANOVA performed
 
for the test day. In order to assess whether
 
amphetamine produced behavioral sensitization a series
 
of t^tests (P<6.05) were performed to examine how the
 
saline- and amphetamine-conditioned rats responded to a
 
challenge dose of amphetamine.
 
Results
 
Conditioning: Effects of amphetamine on locomotor
 
activity. Overall, rats receiving fepeated treatments
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with amphetamine had significantly more line-crosses
 
than saline controls on each day of conditioning (see
 
Figure 40) [Conditioning X Day interaction,
 
F(4,120)=95.34, P<0.001; and Tukey tests, P<0.05].
 
Amphetamine produced a progressive increase in locomotpr
 
activity across days (upper graph, Figure 40) [Tukey
 
tests, P<0.05J.
 
Testing; Effects of U-50.488 challenge on loconiotor
 
activity in amphetamine-conditioned rats. On the test
 
day, amphetamine-conditioned rats failed to display
 
sensitized locomotor activity following amphetamine
 
challenge (see triangles, right panel. Figure 40)
 
[i:(14)=1.57, P>0.05]. Overall, rats challenged with U­
50,488 had significantly more line-crosses than rats
 
challenged with amphetamine [test main effect, P(1,31)=
 
34.66, P<0.001]. On the test day, there were no
 
significant differences in line-crosses between
 
amphetamine- or saline-conditioned rats in response to
 
U-50,488 challenge.
 
Conditioning: Effects of amphetamine on stereotyped
 
sniffing. Rats treated with amphetamine had
 
significantly more sniffing counts than saline controls
 
on each day of conditioning (see Figure 41)
 
[Conditioning X Day interaction, P(4,120)=3.89, P<0.05;
 
and Tukey tests, P<0.05].
 
Testing: Effects of U-50.488 challenge on
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stereotyped sniffing in amphetamine-conditioned rats.
 
On the test day, following amphetamine challenge,
 
saline-conditioned rats had significantly more sniffing
 
counts than amphetamine-conditioned rats (see triangles,
 
right panel. Figure 41) [t(14)=2.15, P<0.05]. Overall,
 
rats challenged with amphetamine on the test day had
 
significantly more stereotyped sniffing counts than rats
 
challenged with U-50,488 (see right panel. Figure 41)
 
[Condition X Test interaction, F(1,31)=4.26, P<0.05].
 
Conditioning; Effects of amphetamine on circling.
 
Amphetamine did not produce any circling during
 
conditioning (see Figure 42).
 
Testing: Effects of U-50.488 challenge on circling
 
in amphetamine-conditioned rats. On the test day,
 
amphetamine challenge failed to produce any circling.
 
However, amphetamine-conditioned rats challenged with U­
50,488 had significantly more circling counts than all
 
other groups (see right panel. Figure 42) [Conditioning
 
X Test interaction, F(1,31)=20.59, F<0.001; and Tukey
 
tests, P<0.05 J.
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FIGURE CAPTION
 
Figure 40. Mean number of line-crosses of rats given
 
five daily injections of amphetamine (2.5 mg/kg, i.p.)
 
or saline starting at 11 days of age (n = 8). At 17
 
days of age (i.e., after a 2-day interval), rats given
 
successive saline or amphetamine injections were then
 
given a single challenge injection of U-50,488 (5.0
 
mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).
 
158
 
  
1000- -1000
 
800­
Amphetamine During Conditioning Test Day 
-800 
600­ ■600 
400­ -400 
S 200­
CO 
(0 
2 ( 
o 
I 
o 800­
Saline During Conditioning 
A Amph 
□ U50 
Test Day 
-200 
■0 
■800 
600­ ■600 
400­ -400 
200-1 1-200 
0­ o 
11 
o 
12 
o 
13 
o* 
14 
-0 
Age 
159 
FIGURE CAPTION
 
Figure 41. Mean number of stereotyped sniffing counts
 
of rats given five daily injections of amphetamine (2.5
 
mg/kg, i.p.) or saline starting at 11 days of age {n =
 
8). At 17 days of age (i.e., after a 2-day interval),
 
rats given successive saline or amphetamine injections
 
were then given a single challenge injection of U-50,488
 
(5.0 mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).
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Figure 42. Mean number of circling counts of rats given
 
five daily injections of amphetamine (2.5 mg/kg, i.p.)
 
or saline starting at 11 days of age {n =8). At 17
 
days of age (i.e., after a 2-day interval), rats given
 
successive saline or amphetamine injections were then
 
given a single challenge injection of U-50,488 (5.0
 
mg/kg, s.c.) or amphetamine (2.5 mg/kg, i.p.).
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Discussion
 
There was no evidence of crcss-sensitization
 
between U-50,488 and amphetamine. Rats challenged with
 
U-50,488 showed a Similar increase in locomotor activity
 
regardless of whether they were conditioned with
 
amphetamine or saline. Overall, these results suggest
 
that U-50,488 and amphetamine increase locomotor
 
actiyity by affecting different systems.
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General Discussion
 
The purpose of the present study was to examine U-

50,488's paradoxical effects on locomotor activity.
 
More Specifically, iri the adult rat U-50,488 decreases
 
locomotor activity; whereas, U-50,488 dramatically
 
increases the locomotor activity of the preweanling rat.
 
In these younger animalsj the increased locomotor
 
activity produced by. U-50,488 is similar to that
 
obseryed following DA agonist treatment. Therefore, the
 
purpose of these experiments was to determine whether U-

50,488's locomotor activating effects are mediated
 
through a dopaminergic mechanism. Six hypotheses were
 
originally proposed: (1) It was suggested that U-50,488
 
would decrease the locomotor activity of the 80-day-old
 
rat. The results of Experiment Id supported this
 
hypothesis, as all doses (0.2—10.0 mg/kg) of U-50,488
 
reduced the locomotor activity of adult rats. (2) As
 
predicted, U-50,488 increased the locomotor activity of
 
the preweanling rat (see Figures 2 and 7). (3) It had
 
been originally hypothesized that U-50,488 would
 
potentiate amphetamine- and NPA-induced behaviors in
 
the preweanling rat. However this was not
 
substantiated, as NPA actually attenuated U-50,488­
induced locomotor activity (see Figure 7).
 
Amphetamine's actions were less clear, but the results
 
suggest that amphetamine also depresses the behaviors
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of U-50,488 treated rats. (4) Flupenthixol (a
 
nonselective DA receptor antagonist) was predicted to
 
reduce U-50,488-induCed locomotor activity. The results
 
of Experiment 2 supported this hypothesis, as
 
flupenthixol produced a dose-dependent decline in U-

50,488-induced activity (see Figure 6). (5) As
 
predicted, amphetamine and NPA stimulated regional Fos
 
expfession in the preweanling rat. The areas showing
 
the greatest amphetamine- and NPA-induced Fos
 
immunoreactivity were the piriform cortex and cingulate
 
cortex (see Figures 11 and 16). (6) In general, U­
50,488-, amphetamine--j and NPA-induced Fos
 
immunoreactivity did occur in the same brain regions.
 
However, instead of U-50,488 potentiating NPA- and
 
amphetamine-induced Fos, the DA agonists attenuated U-

50,488-induced Fos in the striatum and dlfactory
 
tubercles (see Figures 9 and 10).
 
The results of the present study showed that the
 
kappa opioid agonist U-50,488, the direct DA agonist
 
NPA, and the indirect DA agonist amphetamine, al1
 
independently enhanced behavioral responding in the
 
preweanling rat. High doses of the DA antagonist
 
flupenthixol (0.4 and 0.8 mg/kg) reduced U-50,488­
induced locomotor activity (see Figure 6). This
 
suggests that U-50,488 may have been working via a
 
dopaminergic mechanism. Subsequent experiments indicate
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howeverj that flupenthixol's ability to block U-50,488­
induced locomotor activity may have been diie to a
 
general depression of motoric functioning and not due to
 
direct ihteractions with kappa neurons.
 
To better assess the kappa/DA interaction, U-

50,488-pretreated 17-day-bld rats were given amphetamine
 
or NPA prior to behavioral testing. Although it was
 
predicted that U-50,488 pretreatment would potentiate DA
 
agonist-induced activity, acute treatment with
 
amphetamine had little or no effect on U-5Q,488-induced
 
behaviors. Surprisingly, acute treatment with NPA
 
attenuated U-50,488-induced behavioral responding in the
 
17-day-old rat. More specifically, U-50,488
 
dramatically enhanced locomotor activity, while NPA
 
reduced this activity in a dose-dependent manner. These
 
findings were of particular interest because they
 
indicate that kappa opioid neurons and DA neurons
 
interact to modulate unleaTned activity in the
 
preweanling rat. However, instead of the hypothesized
 
facilitafory mechanism, it appears that the kappa opioid
 
and DA systems have an antagonistic relationship.
 
Consistent with this, there was little evidence of
 
cross-sensitization between the kappa opioid agonist and
 
either of the D'^ agonists. Specifically, U-50,488
 
challenge failed to elicit a cross-sensitized response
 
in amphetamine- or NPA—conditioned rats. One exception
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was that rats receiving NPA or amphetamine during
 
conditioning displayed pronounced circlingfollowing U­
50,488 treatment. This was not true cross-sensitization
 
however, since the circling behavior did not show a
 
sensitized response after repeated amphetamine or NPA
 
treatment. Importantly, regardless of conditioning
 
(i.e., NP'A or amphetamine), U-50,488 produced a dramatic
 
enhancement of locomotor activity oh the test day that
 
was similar to that of U-50,488 alone. Chronic
 
pretreatment with NPA or amphetamine did not affect the
 
enhanced locomotor activity that was produced by a
 
challenge injection of U-50,488 (see right panel.
 
Figures 37 and 40). These results are interesting,
 
because aCute treatment with NPA depressed U-50,488­
induced locomotor activity in preweanling rats (see
 
Figure 35). Overall, these results indicate that the
 
looomotor activaiting actions of U-50,488 may not be
 
mediated directly through a dopaminergic mechanism.
 
In addition to hehayiorai testing, thfeneuronal
 
response to amphetainine and Npa following U-50,488
 
pretreatment was examined by measuring the induction of
 
Fos, the protein product of the early response gene c­
fos. Presumably, increased Fos immunoreactivity is the
 
result of enhanced neurohal activity and, therefore, can
 
be used to identify those brain regions involved in the
 
mediation of behavior (Crawford et al., 1995; Graybiel
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et al., 1990; Sharp, Sagar, & Swanson, 1993). Ip the
 
80-day-old rat, NPA reduce^ Fos expression in the
 
olfactory tubereles, Conversely, NPA increased Fos
 
induction in the piriform cortex, an effect attenuated
 
by U-50,488 pretreatment. In general, NPA's effects on
 
Fos expression are consistent with studies using the
 
direct DA agonist apombrphine, which increased F'os
 
immurioreactivity in the piriform cortex of the adult rat
 
(Wirtshafter & Asin, 1995; Wirtshafter, Asin, & Pitzer,
 
1994). In the present study amphetamine reduced the
 
amount of Fos expression in the zonaincerta, while
 
having only trivial effects in all other brain regions^
 
The dose of amphetamine (2.5 mg/kg) used in Experiment
 
3c may be responsible for the lack of amphetamine-

induced Fos expression. A higher dose of amphetamine
 
(5.0 mg/kg) was shown to induce Fos expression in the
 
striatum and substantia nigra of the adult rat (Jaber et
 
al» , 1995). With the exception of the habenula, U­
50,488 alone did not enhance Fos expression in any of
 
the brain regions examined. In general, this is
 
consistent with the existing adult literature (Crawford
 
et al., 1995).
 
in the preweanling rat, U-50,488, as well as
 
amphetamine and NPA, produced Fos immunoreactivity.
 
U-50,488 enhanced Fos expression in the striatum,
 
olfactory tubercles, pirifprm cortex, habenula, preoptic
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area, amygdala, stria medullaris, cingulate cortex, and
 
septal area of the 17-day-old rat. Of special interest
 
was the striatum, as U-SO,488-induced locomotor activity
 
was accompanied by dramaticaily increased Fos expression
 
in the striatum. NPA treatment blocked both U-50,488­
induced Ipcdmotion and striatal FOs expression. Thus
 
suggesting that the striatum may be one of the brain
 
regions mediating U-50,488's locomotor activating
 
effects. The DA agonists also affected Fos
 
immunoreactivity in other brain regions of the
 
preweanling rat. For example, amphetamine depressed U-

50,488-induced Fos expression in the olfactory
 
tubercles; whereas, amphetamine and NPA enhanced Fos
 
expression in the piriform cortex. These results
 
indicate that while DA agonists can independently
 
affect Fos immunoreactivity, these same DA agonists will
 
modulate U-50,488-induced Fos expression in a number of
 
brain regions.
 
Evidence suggests that kappa bpioids have dual
 
opposing effects on activity: a motor activating effect
 
mediated by non-dopaminergic pars reticulata cells and a
 
motor inhibitory effect mediated through the pars
 
compacta DA cells (Matsumoto et al., 1988; Thompson &
 
Walker, 1990). Redeptor binding studies have indicated
 
that large amounts of kappa opiate receptors are present
 
in the striatum and pars compacta of the substantia
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nigra, with low levels present in the pars retiGulata
 
(Matsumoto et al., 1988; Merchenthaler et al., 1986).
 
Similarly, binding studies have found high levels of DA
 
receptors in the striatum and pars compacta of the
 
substantia nigra, with low level of DA reeeptors in the
 
pars reticulata (Kreiss et al., 1995; Porter, Greene,
 
HigginS, & Greenamyre, 1994; Spampinatb, Gozlan, Daval,
 
Fattaccini, & Hamoii, 1988).
 
Therefore, based on these binding studies it is
 
possible that the striatum is the brain region
 
responsible for the present behavioral data. More
 
speeifically, it is possible that actiVation of the
 
kappa opioid reoeptprs in the pars compacta inhibits DA
 
neurons projecting from the substantia nigra to the
 
striatum. If true, this would account for U-50,488's
 
ability to depress NPA-induced sniffing. Unfortunately,
 
this does not account for NPA's ability to depress U-

50,488^induced activity; At present there is no
 
adequate explanation for this effeet. In general,
 
however, activation of kappa opioid receptors in the
 
adult rat is associated with a reduction of DA-mediated
 
behavior (Crawford et al., 1995; Di Chiara & Imperato,
 
1988; Matsumoto et al., 1988). Therefore, a similar
 
antagonistic relationship between the kappa opioid and
 
DA systems in the preweanling rat is not surprising.
 
In the cross-sensitization experiments, chronic
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treatment with amphetamine or NPA did not affect U-

50,4S8-inducedldcomotor activity (see Figures 37 and
 
40). However, U-50,488 Challenge did produce circling
 
in amphetamine- and NPA-conditionedpreweanling rats
 
(see Figures 39 and 42). Importantly, circling only
 
occurred in rats that had received both U-50,488 and one
 
of the DA agonists. Apparently circling is a kappa
 
opioid mediated effect, but it is only expressed after
 
prior treatment with NPA or amphetamine. Thus it is
 
possible that normal dopaminergic functioning may mask
 
circling, but that the heurobiological changes produced
 
by chronic DA agonist treatment (i.e., changes in
 
receptor numbers, G-proteins, receptor sensitivity)
 
allowed U-50,488-induced circling to be expressed.
 
Curiously, bilateral microinjections of amphetamine or
 
apomorphine into the substantia higra Causes circling in
 
rats (JeTussi & Click, 1976). So it is possible that U­
50,488 and the DA agonists combine to produce circling
 
behavior by activating this brain region. Consistent
 
with this, the substantia nigra is known to have an
 
abundance of both kappa opioid and DA Di and D2
 
receptOTs (Kreiss et al., 1995; Matsumoto et al., 1986).
 
It had been originally hypothesized that the
 
interaction between the kappa opioid and DA systems in
 
the preweanling rat was of a facilitatory nature: That
 
is, it was predicted that U-50,488 would potentiate DA
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agonist-induced locomotor activity. Instead, these
 
systems seem to interact in an antagonistic fashion in
 
the preweanling rat. Thus, this still leaves the basic
 
question of why U-50,488 paradoxically increases the
 
locomotor activity of the preweanling rat, while leaving
 
the activity of the adult rat unaffected. Although the
 
DA system appears to be eliminated as a possible
 
explanation, it is conceivable that ontogenetic changes
 
in NMDA receptors may be responsible for U-50,488's
 
actions.
 
Dizocilpine, an NMDA receptor antagonist, produces
 
a robust increase in locomotor activity in the
 
preweanling rat (Duke, BQlanbs, Garmsen, Clair, &
 
McDougail, 1995; Scalzo & Burge, 1994). Evidence for a
 
kappa/NMDA interaction includes: receptor binding
 
studies showing that high levels of NMDA receptors are
 
located in the striatum and substantia nigra of the rat
 
(Carroll, Holloway, Brotchie, & Mitchell, 1995; Snell &
 
Johnson,,1985). Second, dizociIpine, 1ike U-50,488,
 
increases Fos expression in the striatum (Liu,
 
Nickolenko, & Sharp, 1994). And fina1ly, dizoci1pine
 
produces no cross-sehsitization in rats conditioned with
 
amphetamine or NPA- Thus, dizocilpine's locomotor
 
activating effects, like U-50,488's, do not appear to be
 
mediated thfou^h a dopaminer^ mechanism. Once again,
 
U-50,488 and dizocilpine share the common feature that
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they both dramatically increase the locomotor activity
 
of preweanling rats well above that seen in adults.
 
Therefore, although speculative, it is possible that U­
50,488 and dizocilplne work through common mechanisms
 
independent of actions on DA neurons.
 
In summary, the kappa opioid agonist, U-50,488,
 
dramatically increases the locomotor activity of the
 
preweanling rat. The striatum may be involved in the
 
mediation of this activity, as enhanced striatal Fos
 
expression accompanied the U-50,488-induced increase in
 
locomotor activity. Importantly, the direct DA agonist
 
NPA attenuated Fos expression in the striatum, as well
 
as producing a dose-dependent decrease in U-50,488's
 
locomotor activating effects. The opposite was also the
 
case, NPA-induced sniffing was attenuated by U-50,488.
 
when considered together, these results indicate that
 
the DA and kappa systems have a generally antagonistic
 
relationship with each other. The lack of cross-

sensitization between U-50,488 and amphetamine or NPA
 
provides further evidence indicating that U-50,488's
 
locomotor activating effects are not mediated directly
 
through a dopaminergic mechanism. One possibility is
 
that U-50,488's locomotor activating effects may be
 
meditated through a non-dopaminergic mechanism in the
 
striatum.
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